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ABSTRACT
The current study utilized the Atlantic Blue Cross
Prescription Drug Database to examine patient: refill
compliance to antidepressants from the tricyclic and
selective-serotonin re-uptake inhibitors (SSRII classes. The
primary goals of the study were to describe and compare
compliance between the tricyclic and SSRI users, to
ascertain whether patient age and gender, treatment cost,
and regimen complexity were predictors of non-compliance,
and to evaluate the problems involved with utilizing the
Atlantic Blue Cross Database for compliance research.
Non-compliance was measured by using three outcome
measures. First the percentage of non-compliant days
(defined as the percentage of days during treatment without
medication) was found. Second, the early medication
'stoppers' were compared to the medication 'continuers'.
Finally, the time course of non-compliance was studied by
finding the time till the first non-compliant gap for users.
Resul ts showed that the mean percentage of non-
compliant days was 8.4% (95% eIi 7.9-8.9) for the tricyclic
and SSRI users who filled more than one prescription. In
addition, between 8.1-11.4~ of users stopped the
antidepressant medication early. Survival analysis suggested
iii
that the greatest drop in the cumulative probability of
having a non-compliant gap occurred early in treatment for
both classes. No differences were found in the comparisons
of the tricyclics and the SSRI's in terms of non-compliance.
The predictor variable age was weakly associated with non-
compliance; as age increased, non-compliance decreased. In
addition, regimen complexity as measured by the number of
concurrent medications and the number at doses per day was
also weakly associated with non-compliance. More
specifically, as the number of concurrent medications
increased, compliance increased and as the number of doses
per day increased, compliance decreased.
A number of problems were identified with the Blue
Cross Database. In a number of cases, data was missing. Data
contamination problems were identified that were probably
the result of data entry errors. Cleaning protocols were
developed to deal with some of these problems ..r.. number of
other problems were also identified which were inherent to
the database. E'or example, there was a lack of documentation
concerning dates of entry and exit to the Blue Cross
Program.
iv
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INTRODUCTION
Compliance to drug regimens by patients is a major
determinant of the clinical and cost effectiveness of drug
treatments. Studies have shown that regardless of the
patient population, the disease state, or the compliance
measurement used, compliance rates usually fall well below
100% and that long-term medication therapies tend to elicit
less compliance than short term therapies (Rogers and
Bullman, 1995).
Non-compliance to drug therapies has been measured in a
number of different ways. Several studies have looked at
patterns of prescription fill and refill in a population by
utilizing databases. An advantage of this method is that
researchers do not contact the patients and thus, do not
influence compliance. In population research using
databases, non-compliance can be inferred from several
indicators. E"irst, gaps irr tr-eatment as e'Jide!:!.~ed by qar:s
between prescription refills are indicators of non-
compliance. In many cases compliance is quantified by
calculating the percentage of days during treatment that
individual is without any medication as indicated by the
gaps in refill. A second method of measuring compliance
looks at the individuals who discontinue taking the
prescribed medication early. This method, unlike the
previously described one, looks at those people who
completely stop the medication as indicated by a failure to
return to the pharmacy for refills of tbe prescription. Both
of these compliance outcomes were examined in the current
study.
These outcome measures were compared between two
classes of antidepressants, the tricyclic antidepressants
(e.g. Imipraminel and the selective serotonin re-uptake
inhibitors (SSRI's, e.g. fluoxetine, sertralinel. It has
been suggested that these two particular classes of
antidepressants are nearly equivalent in clinical
effectiveness but the tricyclics are tolerated less well due
to more adverse side effects such as cardiotoxicity,
psychomotor and anticholinergic effects (Montgomery, Henry,
McDonald et a1., 1995). Thus, research suggests that
compliance to the tricyclic drugs is worse than compliance
to the SSRI's (Anderson and Tomenson, 1994\. A problem with
much of this research is that the data has been taken from
clinical trials. Many researchers feel that conclusions
concerning compliance cannot be drawn from such controlled
data. They have suggested that definitive conclusions
only be drawn from data taken from settings such as
population-based studies.
Recent studies that have used popUlation data to look
at medication compliance have found a number of variables
that may have value in the prediction of non-compliant
behaviours. More specifically, it has been suggested that
the complexity of the medication regimen, the cost of the
medication to the user, and certain demographic variables
may aid the health care provider in predicting whether or
not a patient will comply to a specified regimen of
treatment. The value of identifying these potential
predictors is great. Interventions designed to improve
compliance can focus on the potential predictors and attempt
to lower non-compliance based on changes in these
predictors.
The demographic variables age and sex were examined in
order to ascertain whether they influence the compliance
measures. The effect of age on compliance is quite
controversial. Research has shown positive, negative, and no
effects of age on compliance to a variety of medication
regimens. The effect of patient age on compliance to
a:ltidepressant medications was examined in this study
because it has not been directly examined in a population
(database) setting before. Patient gender has also been
widely examined in regards to compliance. Most research does
not show any association between an individual's sex and
their drug compliance behaviours. However, it was valuable
to study this variable in relation to antidepressant
medications because of the distinct demographic protile of
these drugs. In particular, approximately 70".: of
antidepressants are prescribed to females (Wagner,
Plekkenpol, Gray et al., 1992).
The literature suggests that the complexity of the
medication regimen may impact on the level of patient
compliance. Regimen complexity is thought to be influenced
by such factors as the number of doses of medication per day
and the number of concurrent medications that an individual
is taking (Christenson, 1978). These factors have been
studied in relation to other medications such as the lipid-
lowering drugs and results have suggested that increasing
the number of concurrent medications or the number of doses
per day inversely impacts on compliance (Jones, Gerkin, Lian
et al., 1995; Hamilton and Briceland, 1992). Again,
research is deficit in terms of population studies which
attempt to ascertain the impact of medication complexity on
compliance to the tricyclic and SSRI antidepressants.
The notion that cost of treatment may influence
compliance has been explored in a number of studies. for
example, Thompson and McMillan (1995) examined the effect of
a varying deductible (the base amount that an individual
paid before insurance took over the drug costl on refill
compliance to lipid-lowering medications in a Saskatchewan
population. They found that the odds of stopping the
medications increased marginally for each $10 increase in
patient cost. Varying patient cost has not been studied in
reference to compliance to antidepressant medications. The
Atlantic Blue Cross Insurance plan which has a number of
different insurance co-payment levels provided an excellent
opportunity to compare subscribers who pay varying
percentages of the total prescription cost for the same
antidepressant medication. A second cost factor was examined
in this study that has not been previously researched; the
cost that a person was paying for other concurrent
medications.
A large population database, The Atlantic Blue Cross
Prescription Database, was used as a source of data. The
use of a private administrative database allowed for the
study of problems inherent in the database such as
contamination and incompleteness of the data, and for the
development of data cleaning strategies.
A number of specific study objectives have been
identified. The first five objectives relate to the actual
study of patient compliance to antidepressant medication and
the potential predictor variables of compliance. Objective
number six relates to the use of an administrative database
for the study of cOlnpliance.
The study objectives are;
1. To describe the sample of antidepressant users in the
Blue Cross database in terms of extent of non-compliance.
2. To determine whether differences in level of compliance
exist between individuals using antidepressants from the
tricyclic and SSRI classes.
3. To ascertain whether medication complexity as
demonstrated by the number of concurrent medications per day
and the number of doses per day effect compliance t.o the
tricyclic and SSRI antidepressants.
4. To determine whether the demographic variables, age and
sex, are predictors of compliance to antidepressants from
the tricyclic and SSRI classes.
5. To est.ablish whether the average cost paid per
prescription for the antidepressant medication and for other
medications impact on patient compliance.
6. To evaluate some of the problems and complications
involved with utilizing t.he Atlantic Blue Cross Database for
compliance research.
2 LITERATURE REVIEW
2.1 General Compliance
Patient compliance is a concept that is deeply rooted
in the history of medicine. From the time of Hippocrat.es,
physicians were able to learn about t.he t.herapeutic
effect.iveness of medicinal remedies by observing whether or
not the patient t.ook all of the port.ions of the medication.
In recent years prescription drugs have become more widely
accessible and drug regimens increasingly complex,
especially for many chronic ailments where long term
treatment is necessary_
This literature review focuses on patient compliance,
in particular compliance to antidepressant medications.
General compliance will first be discussed. More
specifically, the significance of non-compliance in
predict.ing medication outcomes will be discussed. In
addit.ion, past methods of studying compliance along with
their associated problems will be explored. Following this,
a brief description of the antidepressant classes being
studied in the current project will be done. Next,
compliance to antidepressant medications will be discussed.
Finally, in the context of the current study, potential
predictors of compliance as well as outcome measures drawn
from previous database studies will be described.
2.1.1 Wha.t is Comp1iance?
Compliance, in a medical context, refers to a patient
following the treatment orders of the physician or health
care provider. Some of the literature distinguishes between
biological and behavioural compliance. Biological compliance
is used to describe the characteristics of a patients
metabolism that allow therapeutic blood levels to be
reached. Behavioural compliance refers to the extent to
which a patient complies behaviourally to a medication
(Frank, Perel, Mallinger, et a1., 1992). It has been
suggested that these two types at compliance will interact
to determine the results of a specific medication for an
individual. In this study, the term compliance will be used
to denote behavioural compliance.
2.1.2 Forms of Non-compliance
How do people demonstrate non-compliance to their
medication :cegimens'? Research suggests that non-compliance
can take several forms. Gerbino (1993) states that although
the origins and motivations for non-compliance are complex,
the manifestation of non-compliance is quite distinct. He
lists five different forms of non-compliance; III not having
the prescription filled, (2) taking an incorrect or wrong
dose (this may involve taking too much or to little), (3)
taking the medication at the incorrect time, (4) forgetting
to cake one or more doses, and (5) stopping the medication
too soon. In the first form of non-compliance, t.he patie.nc
rejeccs the treatmenC plan as recommended by the healch care
provider and does not have the prescription filled. In the
second, third, and fourth forms of non-compliance, the
patient accepts the treatment plan but does not comply to it
by taking the wrong dose, taking it at an incorrect time,
forgetting doses, or taking too many doses. In the final
form of non-compliance, the patient may stop taking or
refilling the prescription sooner than was recommended by
the health care provider.
2.1 3 Significance of Non-compliance
Does non-compliance result in an increased risk to
patient health? A considerable number of studies have looked
at the effects of non-compliance to different medications on
patient outcomes. Results from these studies suggest that
pati~nts who do ~ot take !lledicaticns as ~eccmmended ·.... ill :'l0::
receive benefits from the medication. this could adversely
affect the patient's health (assuming the medication is
effective). Rovelli, Palmeri, Vossler, et al. (1989) looked
at compliance to immunosuppressive medications and outcomes
from organ transplants. In the prospective portion of their
study, 30 of 182 patients were considered non-compliant. 37%
of the non-compliant group experienced organ rejection or
death as opposed to only l~ of the compliant group. The
authors concluded that non-compliance with immunosuppressant
therapy is a major factor in tissue rejection, causing more
transplant failures than uncontrollable rejection in
compliant patients. This study illustrates a case where
compliance to medication can have dire consequences; death.
Non-compliance is also a problem with medications for
chronic conditions where such immediate threats are not a
concern. Table 2.1 shows a summary of nine studies that have
looked at outcomes of non-compliance to various long-term
drug therapies. Lack of compliance to antihypertensive,
anticonvulsant, lipid-lowering, and depressive medications
resul ted in poor outcomes in the study populations.
The problems associated with non-compliance to
medication regimens often affect more than the individual
being treated. Rogers and Bullman (1995J suggest that
infections may linger or become resistant to tr~at.me!:!.t and
infectious diseases such as tuberculosis are spread, in
part, because of the effects of non-compliance to the
appropriate treatments. Thus, good health outcomes appear to
be related to compliance to the appropriate medications.
However, Michenbaum and Turk (1987) caution that compliance
to treatment recommendations is only one factor that
influences outcome.
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Tab~e 2.1.: Summa.:v of N.ine Research Studies that Looked. ;at
the Re.l.;ationsni.p of comp1i.~C8 and. OUtcomes
Reference Study
Type
Study Objective
E'saty et
a1., 1990
Bond et
al., 1984
Maronde et
al., 1989
Gallagher
et al.
1993
Canner,
Coronary
Drug
project,
1980
Case
Control
Case
Control
Cohort
Random-
ized
Double
Blind
Multi-
centre
trial
Random-
ized
Double
Blind,
Placebo
controlle.
multi-
Looked at relative
risk of first events
in coronary heart
disease associated
with poor compliance
to J3-blockers in
hypertensive patients
Analyzed Effect of an
intervention on
improving drug
compliance and
documentation
Looked at
underutilization of
antihypertensive drugs
and subsequent
association with
hospital re-admissions
Examined relationship
between compliance to
medication regimens
leg. E'ropranol) and
mortality following MI
in women
E,,~aluated Efficacy and
Safety of several
lipid-lowering drugs
in the long-term
treatment of coronary
heart disease
1\
Those who stopped Il-
blockers had a RR of
4.5, (95!; 1.1-18.51
of first event.; Tho$
who were less
compliant were more
likely to stop therap
Significant
Correlation between
compliance and Blood
Pressure Control;
correlation
coefficients !'anged
from .67 to .89 for
different study group:
Group re-admitted to
hospital had
significantly higher
ratio of days when
they were without
antihypertensive
agents
Death occurred in
l3.6! of poor
compliers compared
with 5. 6~ in good
compliers; RR "'" 2.4,
19S~ CI, 1.1-5.6)
Good compliers who
took 80% or more of
the protOCOl
prescription during
the five year study
period and had a
substantially lower
five year mortality
HCCombs et
a1., 1994
Stanaway
et al.
1985
Frank et
a1. 1992
Col et a1.
1990
centre
clinical
trial
Cohort
database
Cohort
database
supple-
mented
by
patient
interv-
iews)
Random-
ized
Clinical
Trial.
Cohort
Explored association
between interruption
or termination of
antihypertensive drug
therapy and total
health care costs
among non-
institutionalized
patients
Attempted to ascertain
whether non-compliance
with anticonvulsant
therapy with
associated with or
precipitated seizures
Examined the
relationship between
long-term medication
compliance and to
prophylaxis in
recurrent unipolar
depression
Examined the role of
medication non-
compliance and adverse
drug reactions in
hospitalizations in
the elderly
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than did poor
compliers (15 vs.
24.6'!. respectively)
~atients with
interrupted therapy
consumed an addition
5813 (U. S.) per pers
in health care
expenditures
Non-compliance was
found to be
instrumental in
precipitating 31:. of
seizures for which
ambulance was called
31, of patients were
not taking their
medication in
accordance with
prescribing
instructions.
Medication compliancl
was found to be
significantly
associated with
effective prophylaxi~
(p '" .04)
About 11., of
admissions ot older
patients to an acute
care hospital W'ere
directly related to
some form of non-
compliance. Total co.!
per patient was S2lSC
(US)
Another siqnificant issue related to non-compliance is
the potential associated costs. According to Rogers et al.
{l9951 the costs associated with non-compliance can be
broken down into two categories; (l) direct costs and (21
indirect costs. Direct costs include such things as initial
prescriptions which do not produce desired results because
they are not taken properly and additional prescriptions
which may not have been needed had the initial prescription
been complied to. Also, additional physician or clinic
visits, emergency room visits, hospitalizations, additional
diagnostic tests, nursing home admissions, and home health
care services may become necessary due to lingering problems
or illnesses which could have been cured or managed had the
initial prescription been complied to as recommended.
Finally, additional care for the consequence of uncontrolled
chronic disease such as heart attacks may become necessary
if the initial preventative therapy le.g., antihypertensive
medications) is not complied to. In contrast, indirect costs
of non-compliance to a prescribed regimen might include lost
productivity or absenteeism in the work place, lost
earnings, and employee turnover due to premature death or
disabili ty.
A number of studies have looked at direct costs of
non-compliance. For example, Table 2.1 shows three studies
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in which nan-compliance had direct cost implications.
McCombs, Nichol, Newman et al. (1994) found that non-
compliance resulted in increased health care casts in
patients taking antihypertensive medications. Col, E"anale,
and Kronhom (1990) also found that non-compliance was
related to hospital admissions in the elderly. Maronde,
Chan, Larsen et al. (1989) found that re-admissions to
hospital were more frequent in non-compliant patients. These
studies suggest that non-compliance has significant
implications for cost. Few studies have gone as far as to
look at the indirect cost implications of non-compliance.
2.1.4 Methods for Studying Non-Compliance
Compliance has typically been studied in clinical trial
settings through the use of such methods as patient self
report through interviews or questionnaires, pill counts,
electronic monitoring, or drug monitoring through blood or
urine tests. A number of problems exist with these !!!.eth~ds.
Patient self reports of medicat.ion use have been shown
to be inaccurate when compared with more objective measures.
Park and Lipman (1964) found t.hat in 40% of cases, patient
self reports did not match pill counts. Gordis, Markowitz,
Lilienfeld (1969) also found that in children taking
penicillin prophylactically, discrepancies existed between
reported compliance and urine tests for the penicillin.
Responses of patients and their mothers suggested that 70"!
were compliant. Urine tests showed that only JJ to 42~ had
confirmatory urine levels of penicillin.
Pill counts or the comparison between the amount of
medication remaining in a patients bottle and the amount
that should have been left is a commonly employed method in
compliance research. Like the other methods described this
measure is not without problems. fletcher and Pappius (1979)
suggest that it is difficult to ensure that all pills
brought to the clinic for counting. This is especially true
for patients who want to convince the researcher that they
have been compliant. to their medication regimen. Other
comparative studies suggest that pill counts tend to
overestimate compliance. For example, Roth and Berger (1970)
found a 36% discrepancy rate between tablet counts and
physiological measures in a study looking at treatment of
peptic ulcer patients.
Recently a number of electronic devices have been used
for such things as the monitoring of doses, self-testing,
and outpatient notation of events (Cramer and Spilker,
1991). These devices use microprocessors which record the
time and date that the bottle or apparatus was used to
dispense a dose of medication. This method has been shown to
be very useful in compliance research because it allows the
"
researcher to ascertain that the initiative of opening the
pill bottle actually occurred. However, this method is
expensive to use on a large scale basis and patients may
fool the system by opening the lid an excessively large or
small number of times or by putting the medication in other
containers.
Drug monitoring through blood or urine tests is often
considered the gold standard in compliance research (Steiner
and Prochazka, 1997). It is a direct method of measurement
which does not rely on patient recall. However, there are a
number of problems associated with this method including the
type of medication being measurl!!d and individual
pharmacokinetic variations. Cramer et al. (1991) state that
measurement of drug serum concentrations can indicate
erratic compliance. However, she notes that, for medications
with short half lives serum levels reflect only recent doses
not doses missed several days before the test. Gordis{1979\
states that differences in individuals in absorption,
distribution, metabolism, and excretion of drugs is also
issue in measuring patient compliance with this method.
Genetic differences and bioavailability, defined as the
amount of the drug absorbed from a certain formulation of
the drug relative to the amount of the drug absorbed from a
standard reference, are thought to be a major confounders
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when studying compliance via biological measurement.
As a group, these methods of measurement are very
obtrusive in that patients are aware that compliance is
being measured. Because compliance is a behaviourally
rooted phenomenon, non-intrusive methods must be used in
order to avoid the Hawthorne effect which suggests that
subjects will modify their behaviour when they know that
they are being studied (Forsyth, 1990). In other words, if
subjects know that compliance to medication is being studied
they may be more likely to comply in order to aid the
researcher. In addition, it has been suggested that data
from clinical trials, where compliance is not the primary
research question, is not a good indication of compliance
because a great deal of effort is devoted to getting
subjects to comply with their medication. This is especially
necessary when treatment effects of medications are being
studied because effects cannot be properly evaluated if
compliance is low in either group (Paykel, 19951. Recent
research has used population databases as an indirect,
obtrusive, method of studying patient compliance to
medication regimens.
2.1 5 Use of Databases to study Compliance
Use of large population databases in compliance
research is a relatively new occurrence made possible by
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advances in computers and data Dlallagem.ent. Patterns of
utilization or prescription fill and refill can be
ascertained from the database. Like several of the methods
described above, interring compliance from databases is an
indirect method of measurement because one cannot observe
the compliance behavior. An advantage of using databases is
that they are a non-obtrusive method of studying compliance.
As opposed to the methods described above, databases allow
the researcher to obtain information about subjects without
directly contacting or involving the subjects_
Results from a number of database studies suggest that
data from randomized clinical trials may not reflect
patterns observed in population-based settings. Andrade,
Walker, Gottelieb et 0.1. {l995) used computerized records
from a HMO to look at discontinuation before one "jear in
users ot antihyperlipidemic drugs. They reported that the
probability of discontinuing therapy within the first year
ranged from l5-46~ depending on drug class. This differs
from previously reported discontinuation races within the
first year in clinical trials of between 4-15~ (Bradford,
Shear and Chremos, 1991). Similar results to the Andrade et
0.1. (1995) study were found in several other studies.
Thompson et 0.1. {l9951 looked at lipid-lowering medications
and discovered that discontinuation rates after filling one
"
prescription ranged from 30 to 38%. Lacour and Lelorier
(199S), in a population database study, found that the
probability of still being on lipid-lowering medication
after one year of treatment varied bet.ween 4l-11.2~. Simon,
Levis, and Simon (1996) looked at patients who failed to
collect prescription refills for lipid-lowering drugs and
found that 60% discontinued treatment in the first. six
months. Each of these studies suggest that the rates of
discontinuation for the lipid-lowering medicat.ions may be
higher in the general population than is suggested in
clinical t.rials. This is largely due to the fact that
clinical trials are not typically desiqned to measure
compliance. In addition, much effort goes into getting
subjects to comply to the medication in order to observe the
effects of therapy.
Compliance outcomes from databases have been defined in
a number of ways. Lacour et aI. 11995} suggest th3.t:
databases allow one to view compliance from two
perspectives; (1) percentage of days without medication or
gaps in treatment and (2) probability of a permanent
treatment interruption. One criteria when inferring
compliance from a database is that the treatment of interest
must be of long-term duration and necessitate the filling of
a number of prescriptions. Compliance to therapies with a
"
potential life-long duration such as lipid-lowering drugs
and antihypertensive medications have been widely studied
using databases (Andrade et al. ,1995; Jones et al., 1995;
Maronde et.al.,1989; Thompson et al. , 1995; Bond and
Monson, 1984; Psaty, Koepsell, Wagner et al., 1990). Most of
these studies utilized outcome measures in which either gaps
in treatment or numbers of days with or without medication
and total treatment discontinuations (i.e. stopping
medication prematurely) were considered.
The use of databases to study compliance does have
inherent problems. first, using prescription refill patterns
to ascertain compliance is an indirect measurement. We
assume that a person is compliant to the medication if they
fill prescriptions for the recommended amount of medication
over a recommended period and refill a new prescription
before or at the end of that period. However, a person's
refill behaviour may not necessarily r~flect !:hei~ ~c!:ua!.
drug-taking behaviour. Medications lost, shared with family
members, or simply not taken at all may lead to an
overestimation of compliance. Medications obtained from
other sources not available to the researcher may cause an
overestimation of non-compliance.
Databases are also limited by the accuracy of data
entry. It has been suggested that administrative databases
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such as those kept by pharmacies may have precision problems
that occur at the data entry level (Katzelnick, Kobek,
Jefferson et al., 1996).
A third problem that is often inherent. in databases,
administrative databases in particular, is that specific
data such as diagnostic information, are usually not
collected. This problem will vary depending on the database
utilized and the information needed. For example, lack cof
diagnostic information is a problem when examining
medications that may be prescribed for several different.
indicat.ions such as antidepre:ssants (t.his will be discussed
further in the next section).
A final problem involving data availabilit.y is
that hospital stays during the period of treatment may
create artificial gaps in treatment because medications
dispensed in the hospital may not be recorded in a community
(i.e. pharmacy, insurancel database !Stein'!r, KoepS"~lL
Fihn, et a1., 1988).
2.2 Antidepressant Medications
2.2.1 Indication
The antidepressant. medication:s are an heterogeneous
group of drugs which share major therapeutic effects; in
particular, the treatment of major depressive disorder
(MOD). Although utilized primarily for depressive and other
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psychiatric conditions such as panic disorder and obsessive-
compulsive disorder (OCD), these drugs also prove effective
in the treatment of a number of other conditions (see Table
2.2). McCombs et a1. (1990) found that two thirds of
patients who are using antidepressants may be under
treatment for problems other than MDD. Since lesser levels
of depression that do not fall under the umbrella of MDD
would be included in the other two thirds, it is still
likely that a large portion of users are taking
antidepressants for some form of depression.
There are several major classes of antidepressant drugs
including- III the tricyclic antidepressants, (2) the
serotonin-selective re-uptake inhibitors (SSRI' s), (3) the
monoamine oxidase inhibitors (MAOI'sl, and the heterocyclic
antidepressants, and the Serotonin - Norepinephrine Re-
uptake Inhibitors (SNRI's) (see Appendix I). This paper will
focus only on the two most commonly pr-escrib-ed classes, t;he
tricyclics and the SSRI' s. It should be noted that the
guidelines for such things as dosing apply to those
antidepressants prescribed for the indications of
depression. There is a noticeable lack of specific
prescribing guidelines for antidepressants for other
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Table 2.2: Drug Names and Classes with Associated
Indications for Use
DROG (CLASS)
All Classes
Imipramine (Tricyclic) 1
Various SSRI' s 2
Imipramine 1
Doxepin (Tricyclic)
Trimipram.ine (Tricyclic)l
Doxepin (Tricyclic)
Trimipramine (Tricyclic)
Amitriptyline (Tricyclic)
Maprotvline (MAOI) 1
Protrictvline (Tricvclicl l
Fluoxetine and other SSRI's
Desipramine (Tricyclic) 1
Desipramine (Tricyclicl l
Imipramine (Tricyclic) 1
Amitriptyline (Tricyclic)
Trazodone 1
Imipramine l
Clomipramine !Tricyclic! 1
Fluoxetine (other SSRI as
well) 5
Amitriptyline (Tricyclic, 10-25
mq incremented3
Tricyclic (low dose) 3
INDICATION FOR USE
Depressive Disorders;
depression, depressive phase of
bioolar disorder, dysthroia
Treatment of School Phobias and
Panic Attacks
Childhood enuresis
Palliation of peptic ulcer in
depressed patients
Symptomatic treatment of
dermatologic allergies with
pruritus
Hypersomnia and sleep apnea
Bulimia nervosa
Cocaine Dependence
Narcolepsy manifesting
predominantly with cataplexy
Palliation or prevention of
pain syndromes and migraine
Attention deficit disorder
Obsessive-compulsive disorder
Abdominal Pain caused by
irritable bowel syndrome
Management of angina-like chest
I cain of esophageal origin.
- Berkow (1992)
- Klerman (1992)
- Thomson and Shaffer (1994)
4 - Harris and Kurdyak (1997)
5 - Goodman, McDougle, and Price (1992)
2J
indications such as OCD or panic disorder.
2.2.2 Mechanism of Action
It is important to understand the mechanisms by which
the antidepressant medications work because of the potential
role this may have on compliance to these drugs. Mood
disorders are thought to be, in part, influenced by the
alterations in firing patterns in certain subsets of
biogenic amine-containing neurons in the central nervous
system. The antidepressant drugs tend to playa role in
increasing the concentrations of these biogenic amines in
the brain. Although this action may occur immediately, it
may take several weeks before a change or improvement in
mood is observed. Chronic administration of antidepressant
drugs for several weeks may result in a decreased density of
postsynaptic receptors for serotonin (S-HT; subtype) and
norepinephrine (13 subtype) in the brain tissue. This
phenomenon is known as down-regulae ion and is thoughc co be
a reaction to the increased levels of these
neurotransmitters. Much of the therapeutic effect associated
with antidepressants probably occurs because of the
down-regulation of receptors which may take several weeks to
occur (Brody, Larner, Minneman, Neu, 1994). Thus, from the
point of view of compliance, it has been suggested that the
delayed onset of therapeutic effect may result in greater
"
levels of non-compliance in the beginning stages of therapy
{Myers and Branthwaite, 1992; Maddox, Levi, and Thompson,
1994; Katzelnick et al., 19961.
2.2.3 Tricyclic Antidepressants
2.2.3.1 History and Mechanisms of Action; The tricyclics
were first discovered in the 1950's and 1960's. Imipramine,
the first tricyclic, was initially tested as a potential
antipsychotic compound (Arana and Hyman, 1987). It is
thought that the tricyciics produce their therapeutic effect
by blocking, in different degrees, the re-uptake of
neurotransmitters, including serotonin and norepinephrine,
at the neuronal membrane (Krogh, 1994). Different tricyclics
may vary in their propensity for blocking the re-uptake of
either of these neurotransmitters. For example,
amitriptyline shows a greater proclivity to block the
uptake of serotonin than norepineph.rine (Bernstein, 1995;
Krogh, 1994).
2.2.3.2 Dosing; The tricyclics tend t.o have long
metabolic half-lives, frequently more t.han 24 hours, which
allows for once a day dosing. Tricyclics are typically
started at a low dose with gradual increases as the
therapeutic range is reached (Brody et al., 1994). This
dosage can be increased by SOmg every 3-4 days as side
effects allow. Most treatments should level off at
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approximately 1S0-200mg although the maximum dosage of most
tricyclics 1:s approximately 300mg/day. (Arana et al., 1987;
Practice Guidelines for MOD, 1993) A major problem with the
tricyclics which often leads to treatment failure is
inadequate dosing. This problem may, in part, be explained
by the side effects of these drugs which are more pronounced
at higher dose levels. Several studies have shown that many
general practitioners do not raise the starting dose of the
tricyclics to a level at which the therapeutic efficacy {for
depression) has been shown to be superior to placebo in
clinical trials (Tyrer, 1988; Ketai, 1976; Maddox, et al.
1994) Thus, the selection of an adequate dose takes into
consideration the medications side effect profile, the
typically effective dose range, as well as the patients age
and health status.
2.2.3.3 Side Effects; These drugs do carry a somewhat
troublesome side effect profile. Most of the side effects
are a result of interactions with central and peripheral
neurotransmitter receptors. Antagonism of muscarinic
receptors cause such side effects as dry mouth, blurred
vision, urinary retention, reduced sweating, constipation,
and recent memory impairment. Sedation is caused by the
blocking of the histamine (H,) receptors. Antagonism of the
a-adrenergic receptor:s results in orthostatic hypotension.
2.
Cardiac toxicity is possibly the most dangerous side effect
of the tricyciics which is caused, in part, by the
antiarrhythmic quinidine-like side actions of the tricyclics
on cardiac muscle (Arana et al., 1987). The tricyclics
also quite dangerous in overdose. A 10 day supply of
antidepressants at a dose of 200mg/day, if taken at once, is
most often lethal and ingestion of lesser amounts can also
be quite dangerous. Some of the newer antidepressants (che
SSRI's) are less dangerous in overdose. {Practice Guidelines
for MDD, 1993}
2.2.4 Selective-Serotonin Re-uptake Inhibi tors
2.2.4.1 History and Mechanism of Action: The first
highly potent discriminative inhibitor of serotonin,
fluoxetine, was first developed in the 1970's but was not
marketed in North America until the 1980's (1987 in the
United States). Since that time, several other
antidepressants have been developed which also fall into the
SSRI class including fluvoxamine, paroxetine, and
sertraline. Additionally, venlafaxine is a relatively new
drug which is fairly selective to serotonin but also has a
potent ability to block norepinephrine (Bernstein, 1995).
2.2.4.2. Dosing: The problem of inadequate dosing is
less prevalent with the SSRI's than with the tricyclics
primarily because the SSRI' 5 are manufactured in the
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commonly recommended dosage whereas the tricyclics tend to
come in a wider dosage range with the smaller doses being as
low as 10mg. The SSRI's tend to have long half lives.
Fluoxetine is notable for having a half-life of 2 to 3 days
for the parent drug and up to 7 to 9 days for the active
metabolite, norfluoxetine. Sertraline, a newer SSRI, has a
half life of approximately 20 hours for the parent drug. The
active metabolite, N'-desmethylsertraline, is only active for
approximately 60-100 hours. In general, the SSRI's can be
administ.ered on a one per day basis. {Brody et al., 19941
2.2.4.3 Side Effects; Side effects with the SSRI's tend
to be somewhat less severe than those associated with the
tricyclics. In particular, there are a relative lack of
cholinergic, histaminergic and Ct;-adrenergic side effects.
Essentially, this means that adverse effects such as dry
mouth, constipation, cardiotoxicity, sedation, weight gain,
dizziness, and orthostatic hypotension are not a major
concern with the SSRI's. (Kasper, 1994) In addition, the
SSRI's are relatively safe in overdose especially in
comparison to the tricyclics. {Arana and Hyman, 19871
However, the SSRI's do tend to have several associated side
effects. They tend to cause nausea in some people. This side
effect does appear to resolve somewhat with time. A common
side effect of the SSRI's that may indeed interfere with
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long term compliance is sexual dysfunction. According to
Bernstein (1995), up to one third of SSRI patients
experience reduced libido, arousal, and organismic
functioning.
2.2.5 compliance to Antidepressants
Clinical experience suggests that patients comply
poorly with psychiatric medications (Haynes, 1979). Clinical
data also supports this observation. Katon, Vonkorff, Lin et
al. (1992) found that only 20% of patients who had been
given prescriptions for first generation antidepressants
(amitriptyline, imipramine, or doxepin) filled four or more
prescriptions for the antidepressants in a six month period.
This compared with 34% of patients who had prescriptions
issued for the newer antidepressants (nortriptyline,
desipramine, trazedone, and fluoxetineJ. Lin, Von Korff,
Katon et al. (1995) interviewed patients and found that
approximately 28'& of patients prescribed an ::!.!1t.idepressant.
for depression stopped taking medications during the first
month of therapy and 44'! had stopped taking them by the
third month of therapy. Maddox et al. (l994) also
interviewed patients prescribed antidepressants for any
reason in general practice. They found that 32% of patients
had stopped the medication wi thin six weeks and 63% of these
did not inform their GP of their decision to stop. In all of
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the above studies, side effect burden, at some level, was
significantly associated with the decision to discontinue.
Myers et al. (1992) interrogated patients and counted left-
over pills after four three week periods. They also found
that there was a significant reduction in compliance with
the antidepressants over time. Myers and Calvert (1984)
found that patients who did not comply to treatment in the
first three weeks of treatment were unlikely to comply
further with the same treatment regimen.
These studies suggest that compliance to antidepressant
medication is a problem. As with other medications,
compliance can have significant impact on treatment outcome.
Frank et al. (1992) showed that compliance to antidepressant
therapy is significantly associated with effective long-term
prophylaxis in recurrent depression. In addition, Gerbino
(1993) suggested that, in people prescribed antidepressants
for depression, no people who took less than 80'! of their
medication doses recovered. Little research has been done
looking at the association between compliance and outcome
for other illnesses that antidepressants are prescribed for
such as bulimia nervosa and obsessive compulsive disorder.
Much of the literature on antidepressants has compared
the original tricyclic antidepressants with the new
generation SSRI's. Research suggests that both classes
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equally efficient in the treatment of depression. However,
it has been suqqested thac the SSRI's are better complied to
because of cheir improved side effect profile. Montgomery
and Kasper 119951 performed a meta-analysis of 67 published
controlled clinical trials comparing the SSRI's and che
tricyclics. They found that, although both classes were
similar in efficacy for depression, the SSRI's were better
tolerated as indicated by longer intervals till
discontinuation. In another meta-analysis of 42 randomized
controlled trials, Montgomery, Henry, McDonald ec al. {1994i
found that disconcinuations because of side effects were
greater with the tricyclics than with the SSRI' s. However,
discontinuations due co inefficacy were the same for both
classes. This study reinforces previous literature which
suggests that efficacy is similar for both classes (in terms
of treatment for depression). In addition, it suggests that
the classes may differ in compliance because of side
effects. Maddox et al. (1994) interviewed pacients who
recently started courses of antidepressant therapy. They
found that the SSRI' s did show a slight , but not
significant, compliance benefit. They suggest that this
difference may have been due to side effects or due to lack
of treatment efficacy with the tricyclics because of the
large percentage of sub-therapeutic doses prescribed.
JI
Simon, VonKorff, Wagner, et al. (1993) used refill
records from a HMO database to look at patterns of
antidepressant use in communi cy pract.ices. In particular,
they examined two potent.ial predict.ors namely inadequate
dose and duraticn of antidepressant t.herapy. They found that
early discontinuation of antidepressant medication (24-35!
in first month) was common and that the older
antidepressants (i.e. tricyclics) had slightly higher
discontinuation rates. In terms of dose, they found that
fewer than half of episodes of therapy had a dispensed dose
that exceeded recommended standards for depression and
again, this was most prevalent in the tricyclic
antidepressants.
2.2.6 Use of Databases in Antidepressant Research; Probl.ems
and Benefi ts
Several studies have used databases to look at various
aspects of antidepressant u~iliza1:ion. !t is evide!'!.t. !:"c:n
these studies that there are a number of problems and
benefits associated with che use of databases for studying
antidepressants. Few database studies have actually looked
at compliance to antidepressants. Several studies were
identified in which utilization patterns, discontinuations,
and costs of therapy were ascertained from prescription
refill records. These studies were all carried out in HMO
"
settings in the United States (Simon et al.,1993; Katzelnick
et al., 1996; McCombs, Nichol, Stimmel et al., 1990; Katon
et al. 1992; Lin et a1. 1995). In each of these studies, the
use of databases provided access to large populations of
antidepressant users. Unlike clinical trials, the use of
databases allowed the researchers to unobtrusively look at
compliance. Katon et a1. (1992) suggest that data coming
from a community setting, as is the case with the
information in the databases, provides a more valid picture
of utilization problem.s such as com.p1iance than would
clinical trial data. Patients selected for clinical trials
are typically highly motivated for treatm.ent, and are
generally excluded if they have serious concurrent medical
or psychiatric illnesses_
A nwnber of problems were also identified for using
databases to look at compliance to antidepressant
medications. First, in several studies, t.he databases did
not provide reasons why patients discontinued or had gaps in
therapy. Thus, little information could be obtained on the
influence of drug efficacy or side effects on
discontinuations. Although the gaps in treatm.ent could have
been due to side effects or to lack of efficacy, this cannot
be inferred from the database.
A second problem was that most databases contained no
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information on other treatments such as psychotherapy that a
person might be undergoing. It has been suggested that this
problem can only be corrected by directly interviewing
patients. (Katzelnick et al., 1996)
A third and final shortcoming that was identified was
the determination of indication for treatment. Most of the
databases utilized did not contain reliable information on
indication (McCombs et al., 1990; Simon et al., 1993,
Katzelnick et al., 1996) This presented particular concerns
when studying antidepressant medication because of the wide
range of illnesses that the drugs can be prescribed for.
This is particularly problematic for compliance research
because the illness itself may impact upon compliance. In
addition, research showing standard doses and drug efficacy
is often illness specific. In relation to the
antidepressants, most of the research relates to depressive
disorders.
2.3 OUtcome Measurement
Outcome measures which utilize information from
prescription refill records result in indirect measures of
patient compliance to medication. The underlying assumption
of such research is that prescription claims accurately
reflect patient use of medication. In addition, it assumes
that the information that is recorded is accurate and
'"
reliable. The benefits of using refill records is that they
can provide otherwise unavailable information concerning
patterns and timing of drug exposure (Steiner et al., 1997).
Also, refill records are often more easily and cheaply
accessed than other information such as information from
patient interviews or pill counts.
A large typology of methods for assessing refill
compliance from computerized pharmacy records have been
utilized in the literature. Lacour et al. (1995) have
classified these measures into two distinct categories; (1)
the number and pattern of days during treatment with (or
without) medication and, (2) the probability of permanent
interruption of treatment. The first category involves
looking at refill patterns to assess whether or not gaps in
treatment may exist. The second measure focuses more on
compliance related discontinuations of therapy. For example,
a treatment discontinuer would be defined as someone who
permanently discontinues therapy before it is recommended by
the health care provider. Research in this area utilizes a
number of subtly different measures which attempt to measure
the extent of non-compliance. Several outcome measures will
be described below which reflect compliance as defined by
either of these categories. These measures have been
utilized in the current study.
"
2 _3.1 Percentage of Non-compliant Days
The percentage of non-compliant days is a measurement of
the number of days with no medication on hand divided by the
duration of the time period of interest multiplied by 100.
fA variation of this measure involves subscitu'ting the
number of days wit.h medication for the number of days
without medication.l This measure lwith or wi'thout the
mUltiplication by 1001 has been used in a number of studies,
several of which have attempted to validate it against other
measures of compliance and outcomes. Steiner et al. (1988)
coined the term Med-Out to represent the ratio of days
without medication to the total number of days of treatment.
They attempted to validate this measure using che records of
subjects taking anticonvulsant and antihypertenive
medications. They compared Med-Out to several physiologic
outcomes of treattnent; plasma pheny'toin levels
lan'ticonvulsantsj and diastolic blood pressure
lantihypertensives). Results indicated that Med-Out.
significantly correlated with the physiological outcome
measures with a Pearson 'r' ranging from 0.30 to 0.42 in the
expected directions. The authors suggested that the results
might be somewhat modest due to misclassification of
patients as compliant who obtained but did not use the
medication. further, they propose that the relationship
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between compliance and drug effect is very complex and would
not be totally due to compliance.
Handless, Mucklow, Smith et al. (1979) also attempted to
validate a similar measure in which the actual number of
tablets received was divided by the theoretical number of
tablets required for that period. They compared this measure
to results from pill counts in a population ot elderly
individuals and found a significant correlation between
tablet counts and the ration of non-compliant days to days
with medication (r "" 0.68, p=.0001).
A number of other studies have also utilized this
measure to determine relevant predictors or associated
outcomes of non-compliance (Monane, Bohn, Gurwitz et al.
1994; Gurwitz, Glynn, Monane, et a1.,1993; Hamilton et al.,
1992; Steiner, Robbins, Roth et al., 1993; Maronde et al.
1989). For example, Monane et a1. (1994) found that the
percentage of days without medication '=l'1er a 12 mcnth pericd
varied by such predictors as age and concurrent medications.
Maronde et a1. (1989) looked at the outcome of rate of
readmission to hospital for hypertensive problems. They
found that those with a higher rate of readmission's had a
significantly higher ratio of days when they were without
any antihypertensive agents relative to the length of time
in the study.
J1
One important factor which did vary between studies
using this outcome measure was whether or not t-he measure
was adjusted to account for oversupplies obtained during
previous prescription intervals. E"or example, an individual
may have returned early to refill a prescription and thus
would have a surplus of pills (this will be explained
further in the methods section). Several studies did account
for this problem (Gurwitz et al., 1993; Steiner et al.,
1988) .
A general assumption that accompanied the use of this
measure was that treatment gaps are due to non-compliance by
the patient rather than drug discontinuation by the
clinician. This is an inherent limitation of utilizing this
type of data and measurement. The percentage of non-
compliant days was utilized in the current study as a
measure of non-compliance to antidepressants.
2.3.2 Early Medication Stoppers Versus Continuers
A second category of non-compliers are t-hose individuals
who discontinue or t-erminate therapy early. These pat-ients
obtain medication only for a short period of time. According
to Steiner et al. (1988), the individuals identified as non-
compliers by the percentage of non-compliant days measure
are different from the medication stoppers in that the non-
compliance index detects patients who are more difficult to
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identify clinically; those people who remain in the health
care system, but fill only some of their prescriptions. In
other words, the percentage of non-compliant days described
above, represents individuals who remain in the system and
continue to get medications refilled. However, they exhibit
non-compliance by not taking the medication on the
recommended schedule.
Early medication stoppers have been identified based on
a number of different criteria. The most popular method of
recoqnizing early stoppers has been to identify chose people
who fill only one prescription (Thompson et al., 1995;
Gurwitz et al., 1993; Monane et al., 1994). The assumption
underlying this criteria is that if a flerson fails to return
for further prescriptions then slhe has exhibited non-
compliance to the regimen, which is assumed to be of a long-
term nature. This can be viewed as primary discontinuation
of therapy or che decision on behalf of the client to desisc
that treat.lnent.
In most of the scudies chat define medication stoppers
people who fill only one prescription, a standard length
of time was evident during which a person would have been on
the medication. For example, Thompson et al. (1995) used
prescriptions that were typically filled on a 34 day basis.
Thus, a person would have had at least a 34 day supply of
medication. Antidepressant medications have unique
characteristics that may influence early compliance. More
specifically, because of pharmacological down-regulation,
individual will probably be taking an antidepressant for two
to six weeks before any therapeutic effects occur (Arana et
al., 198?; Bernstein, 19941. During this time however, side
effects do occur. Consequently, it has been suggested that
people may discontinue early because of side effects and
lack of perceived efficacy (Katon et al., 1992; Lin et al.,
1995; Thompson, Rankin, and Ashcroft, 1982). Thus, several
studies have defined compliance by the duration of time
spent on medication. Those who discontinue the medication
early were considered non-compliers. Lin et al. (1995)
looked at antidepressant stopping using a 30 day treatment
duration (after initial filling) and found that 28~ of
people reported stopping in the first month primarily
because of side effects and lack of efficacy. This 3150
varied between the classes of antidepressants with
discontinuations for the tricyclics being greatest.
2.3.3 Time Till First Non-compliant Episode
Many prescription refill studies have examined non-
compliance in terms of the percentage or number of non-
compliant days. Only a few studies have actually looked at
the duration individuals remain on medication before they
-10
experience compliance problems as siqnified by 'non-
compliant' gaps in treatment. Utiliz.ation of this
measurement involves identifying the first 'non-compliant'
period. This is accomplished by marking a gap of a specified
duration as a non-compliant gap.
The idea of considering a gap of a specified duration as
a non-compliant gap has been done in several studies. Bond
and Monson (1984) considered a patient non-compliant when a
7 day gap in treatment occurred. Thompson et al. (1995)
utiliz.ed much longer intervals of 60, 90, and 120 days to
siqnify discontinuation of treatment to lipid-lowering
medication. Hamilton et al. (1992-) used a variable gap
duration of which was calculated by multiplying 0.2 by the
number of days supply of the previous prescription. For
example, if the previous prescription was for 30 days then a
non-compliant gap would be considered 6 days (30 X 0.2)
between the end of the first prescription and the filling of
a next prescription.
Once a first non-compliant gap has been identified, the
time till this gap can be calculated. This measurement
demonstrates the time course of non-compliance. In ather
words, it provides an indication of when during the
of therapy, individuals first become non-compliant.
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2.4 Predictor Variables
Because compliance to drug regimens is such a
significant predictor of outcome, it is imperative that
predictors of non-compliance be identitied. Previous
research has presented a number at potential predictor
variables at non-compliance inclUding medication class,
complexity of the medication regimen, treatment cost, and
the demographic variables, age and sex. The literature
presents both negative and positive results in tenns of the
predictive value of these variables.
2.4.1 Medication Regimen Complexity:
Christenson (1978) proposes that complexity of the
medication regimen impacts on the level of compliance
because 0 f the contus ion and inconvenience involved wi th
complex regimens. Medication complexity includes such
factors as number of concurrent medications and the number
of doses per day.
2.4.1.1 Number of Concurrent Medications; Previous
research has suggested a strong connection between the
number of concurrent medications that an individual is
taking and the level of compliance. More specifically, many
studies have concluded and it is currently believed that the
more medications that a person is taking, the less well that
person complies to any particular medication. It has been
suggested that this is due to t.he fact that an increased
number of medications are increasingly hard to keep track of
and thus may lead to reduced compliance (Cramer et al.,
1991). In contrast, several studies have also shown that
compliance may actually increase as the number of concurrent
medications increase.
Jones et al. (l99S) looked at discontinuation of and
changes in treatment of antihypertensive medications. They
found that those patients who discontinued treatment had
more concurrent medications than those who did continue the
treatment. Sneddon and Farrall (l989), in a survey of an
elderly population, established that compliance decreased
as the number of items of medication increased. This was
especially pronounced when the number of medications was
greater than three. Larrat, Taubman and Willey {1990j
performed interviews on a population of ambulatory
individuals to ascertain compliance t.o a number of
prescribed medications. They found that participant.s had at
least a two times greater risk ot showing compliance relat.ed
problems if they were taking four or more medicat.ions than
if they were taking fewer than four. Gurwitz et a1. (1993)
looked at prescription refill records to ascertain stop time
and number of days without therapy in elderly individuals
taking glaucoma treatment. They determined that. patients
already taking large number of medications were less likely
to comply to treatment with a new regimen. Kulka (1979)
interviewed and followed charts of individuals treated for
congestive heart failure and diabetes mellitus. She found
that compliance, as measured by patient's reported failure
to take medication as prescribed, increased as the number of
concurrent medications increased.
In contrast to the studies cited above, several
researchers have found that the number of concurrent
medications have a direct relationship to compliance.
Hamilton et al. (19921 used prescription refill records to
assess gaps in treatment to a wide range of drug therapies.
They found that compliance improved as the number of
concurrent medications increased. Monane et al. (1994) found
a similar result when they used refill records to look at
the percentage of days without a prescription for congestive
heart failure treatment. They also found that patients with
the highest use of other medications had the least non-
compliant days with cardiac therapy. These results
challenge conventional beliefs concerning concurrent
medications. Hamilton et a1. (1992) suggest several possible
explanations. First, patients taking multiple medications
may be forced to develop dosage administration strategies
that insure compliance. Second, patients who are perceived
by the health care provider as having complex regimens may
receive more medication counseling than other patients.
2.4.1.2 Number of doses per day; The number of doses of
medication that an individual takes per day has been cited
being a predictor of medication compliance (Cramer et
al., 1991). Most of the literature suggests that, in
general, an inverse relationship exists between the number
of doses per day of a speci fie medication and compliance to
that medication. Puller, Birtwell, and Wiles (1988)
performed patient interviews and pill counts to ascertain
level of non-compliance in type II diabetic patients.
Patient interviews revealed that compliance was similar in
once and twice daily dosing regimens but was worse with
three times daily dosing. Pill counts indicated that
compliance was best with once daily dosing while twice and
three times were both equally inferior. Eisen, Hiller, and
Woodward (19901 uS'!!d blister packs with 212ctr~r:ic
monitoring devices to evaluate the relationship between
prescribed daily dose frequency and medication compliance in
hypertensive patients. Compliance for those with one daily
dose was 83.6% as compared to those with three daily doses
at 59%. Gurwitz et al. (19931 looked at number of days
without medication as a measure of compliance to glaucoma
therapy in an elderly population. They found that people
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using more than 2 administrations per day had more days
without medication than those using 1 administration per
day. A problem with this study was that it was assumed that
medication administration patterns followed usual patterns.
Number of doses per day was calculated based on the usual
number of administrations per day (based on the literature)
for the particular medication prescribed. Widmer, Cadoret
and Troughton (19831 used refill patterns to look at
compliance in antihypertensive medications in a rural
Similar to the other studies, they determined that taking
three or more pills a day was siqnificantly related to non-
compliance. Baird, Bentley-Taylor, Carruthers et al. (1984)
used a randomized controlled trial to look at compliance to
once versus twice daily Betalo~ (Metoprolol) therapy in
hypertensive patients. They also found that compliance, as
assessed by tablet counts, was significantly improved in the
groups receiving once daily therapy. Each of the studies
described above suggest that number of doses per day may
influence compliance. It is interesting that research in
this area has covered a wide range of methodologies from
databases to randomized controlled trials and pill counts.
Kelloway et al. (1994) evaluated compliance and dosing
frequency of two asthma medications by looking at medical
and pharmacy claims records. In contrast to the studies
described above, they did not find any significant
difference in compliance relative to prescribed dose
frequency (twice daily or less compared with three times
daily or more) .
Hamilton et al (1992) utilized a prescription database
to look at compliance to several types of medications. This
database did not provide specific information concerning the
number of adm.inistrations per day. The authors inferred
doses per day from an indirect measure; the quantity of
drugs dispensed divided by the days supply. This measure
gave the apparent number of doses per day. In using this
a measure of number of doses per day, an assumption was
made that each unit of medication was taken separately.
Their finding were consistent with those of other studies,
that compliance generally decreased as the number of
apparent daily doses increased although the relationship was
not linear. Rather, t.he greatest drops in campI iance
occurred after four doses per day. This method of looking at
doses per day is very indirect and does have inherent
problems. However, the authors state that t.he assumption
that each tablet or pill represents one dose is generally
reasonable for most drugs that have a wide variety of tablet
strengths. Antidepres.5ant medications do commonly come in a
wide variety of strengt.hs.
2.4.2 Demographic Variables
Po. great bulk of research has been dedicated, in part, Co
determining whether the demographic variables age and sex
influence patient compliance to medication regimens.
2.4.2.1 Aqe: The literature shows little consensus in
terms of the relationship of age to compliance. Several
studies have suggested that age does have an impact on
compliance. More particularly, several studies suggest that
older age groups are more compliant chan younger age groups.
Thompson et al. (1995) found that users of lipid-lowering
medications who were younger chan 45 were more likely to
stop medication than the most compliant group, 45-74 years.
Simon et al. (1996) also found that the risk of
discontinuation of lipid-lowering medication was lower in
older patients (65+1 than in younger patients. Rovelli et
a1. (1989) also found that older patients were more
compliant to immunosuppressant therapy afte!:" o!:"gan
transplant than were younger patients. Honane et al. (1994)
looked at compliance to congestive heart failure therapy in
an elderly sample and also concluded that compliance was
greatest in the oldest age group 1>85 years). They suggest
that improved compliance in older age groups may be related
to caregiver assistance.
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A large number of studies nave found no association
between age and compliance. Frank et al. (1992) and Lin et
al. (19951 attained no significant age association with
discontinuation rates for antidepressant therapy. Larret et
al. (1990), Sneddon et al. (1989), and Gurwitz et al.
(1993) all determined that age was not a significant
predictor in 60+ age groups for a variet.y of Cherapies.
St.ana·""ay et. al. (1985) found no age related association
with compliance to ant.iconvulsant therapy. Gallagher,
Viscoli, and Horwitz (1993) also failed to detect any
significant age association to antihypertensive treatment in
a female cohort.
As can be detected from the studies cited above, a great
deal of controversy exists as co whecher or not age has any
predictive value for non-compliance. Overall, it would
appear that most studies suggest that no association exists
between the two. In addition, in sev~r-al of the studies that
did show an association between age and compliance, the
association was weak (Monane et al., 1994).
2.4.2.2 Sex; Most of che research looking at patient
gender suggests that it is not a predictor of patient
compliance. Shaw, Anderson, Maloney et ai. (1995) found that
sex was not a significant predictor of compliance to
antihypercensive medicat.ions. Larret et al. (1990) looked at
an elderly population (>60 years) and also found that sex
was not a significant predictor of compliance to general
medication use. Similar results were also obtained by Frank
et a1. (1992) and Lin et a1. (1995) who looked at
compliance to antidepressant medications. A number of other
studies, looking at a wide variety of medications, also
found that sex was not a significant predictor of compliance
(O'Connor, Allen, Hilbert et a1., 1981; Gurwitz, 1993;
Stanaway et a1., 1985)
Beardon, McGilchrist, McKendrick et a1. (1993) and
Andrade et a1. (1995) both found slight differences between
the sexes in terms of compliance, with females being more
compliant. However, in both studies, the authors accounted
for the differences by other variables. Thus, most of the
literature does not support the notion that sex might be a
predictor of non-compliance. Despite this, further study
regarding the impact of patient gender on compl lance should
be done for antidepressants because this variable has not
been studied in a database setting (with regards to
antidepressants I . In addition, antidepressants have a unique
demographic profile. More specifically, approximately 75% of
antidepressants are prescribed to females (McCombs et al.,
19901.
so
2.4.3 Treatment Cost
The effect of the direct patient cost for prescriptions
is a relatively unexplored factor in compliance research.
Most of the compliance studies that have used databases have
used HMO and Medicaid populations. Thompson et a1. (1995)
examined the effect of varying the deductible (i.e.
prescription cost) on refill compliance to lipid-lowering
drugs in a Saskatchewan population. They found that t.he odds
of stopping the medication increased marginally for each $10
increase in patient cost.
Beardon et al. (19931 determined the rat.e of patients
not redeeming their prescriptions by comparing copies of
prescriptions written by general practitioners with those
actually dispensed by the pharmacist in a rural area. They
found that, of those who redeemed prescriptions, 17'! were
not exempt from prescription costs. This compared with 33~
of patients who failed to redeem prescriptions. This
suggests that prescription charges may be related to pat.ient.
refill behaviour.
Shaw et a1. {19951, in a survey of adult. patients on
ant.i-hypertensives, found that 20% of respondents stated
that cost or a lack of money to bUy medications was a reason
for missing doses of medication. This study was based on a
small sample (n=981.
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O'Connor et al. (1981) looked at the number of people
filling their initial prescription. In contrast to the above
studies, they found that there was no difference between
those who filled free prescriptions (social services
recipients l and those who paid for prescriptions. A major
problem with this study was that private insurance plans
were not taken into account.
Most of the studies looking at prescription cost do
suggest that cost might influence compliance or continuation
with a medication regimen. Most studies however, have looked
only at the cost of that particular medication to the
consumer. A gap in the literature exists in that few studies
have looked at the effect of the costs for all other
medications that a person is taking on compliance.
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3 METHODS
3.1 Purpose, Objectives and Hypotheses
The primary goal of the current study was to examine
refill compliance behaviours and identify potential
predictors of refill non-compliance in a sample of
antidepressant users who were subscribers to the Atlantic
Blue Cross Insurance Plans. A number of objectives and
associated hypotheses were developed and are described
below.
The first objective was to describe the sample of
antidepressant users in terms of the problem of non-
compliance as indicated by the three different non-
compliance measures. The first measure, the percentage of
non-compliant days allowed us to look at gaps in treatment
in patients ,...ho continued to have prescriptions filled.
that the mean percentage of time without medication has
ranged from 9% - 31~. (Monane et aI, 1994; Gurwitz et aI,
1993; Steiner et aI, 1993; Steiner et aI, 1988) Based on
these studies, we predict a similar mean percentage of time
without medication for the tricyclics and SSRI' s. The second
outcome measure compared early treatment stoppers to
treatment continuers. Previous studies with antidepressants
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have suggested that between 32% and 35% of ant.idepressant
users discontinue treatment during the first 30 to 60 days
of therapy (Simon et. aI, 1993; Maddox et aI, 1994) _ We
expect t.o find similar discontinuat.ion rat.es in the current.
study_ A final outcome measure that was ut.ilized was t.he
time till the first. non-compliant gap. Literature on t.he
antidepressant.s suggest. that compliance problems may occur
early in therapy due to the extended time till the onset of
action of the medications as well as the side effects of the
medications (Bernstein et aI, 1995). Based on this
information, it was hypothesized that the greatest drop in
compliance would occur early in treatment in the first 1-3
months_
The second objective was to determine whether
differences in compliance exist between individuals using
antidepressants from the tricyclic and SSRI classes. Based
on previous literature (see section 2.2.51, it was
hypothesized that non-compliance would be a greater problem
with the tricyclics than the SSRI's because of their worse
side effect profile. Thus, it was expected that more
tricyclic users than SSRI users would stop medication early.
In addition, the tricyclic users would have a greater
percentage of non-compliant days than t.he SSRI users. Also
class, of medication would be a predictor of the percentage
of non-compliant days as illustrated by a regression
analysis. Finally, it was expected that survival analyses
would indicate that the probabili ty of survival till a
compliant gap in treatment would be significantly less for
the tricyclics than the SSRI' s.
The third objective was to ascertain whether medication
complexity as demonstrated by the number of concurrent
medications per day and the number of doses per day would
effect compliance to the tricyclics and the SSRI's. In terms
of the number of concurrent medications, conventional belief
in much of the literature suggests that, as the number of
concurrent medications increase, the complexity of the
medication regimen also increases, and consequently
compliance decreases. Consistent with the literature,
expected to find that compliance to both the SSRI's and
tricyclic antidepre~sants would decrease as the number of
concurrent medications increase. In terms of the number of
doses per day, the literature suggests that increasing the
number ot times a medication has to be taken each day also
increases the complexity of the medication regimen and thus
decreases compliance. Consistent with the literature, we
expected to find that compliance would decrease as the
number of doses per day increase.
The fourth objective was to determine whether the
"
demographic variables, age and sex. are predictors of
compliance to the antidepressants from the SSRI and
tricyclic classes. Past literature on other drugs as well
on antidepressants (Frank et al., 1992; Lin et al., 1995)
has suggested that sex does not influence compliance. We
expect to obtain the same result in the current study. The
literature has been quite conflicting in terms of the role
of patient age on compliance. A number of studies have
sugqested that age has no impact on compliance (Frank et
al., 1995; Gurwitz et aI, 1993, Gallagher et aI, 1993) while
several studies have implied that as age increases,
compliance increases (Monane et a1., 1994; Thompson et al.,
1995). In addition, in several of the studies that did show
a positive association between age and compliance, the
association was often weak (Monane et al (19951. Since the
majority of the literature sugqests t.hat age does not impact
on compliance and most. of these studies have been carried
out in a similar population database setting, we expect to
see similar results in the current studies for users in both
the SSRI and tricyclic classes
The fifth objective was to establish whether the
average cost paid per prescription for the antidepressant
medication as well as for any other medications an
individual is taking, impact upon compliance to the
,.
tricyclic or SSRI medication. Most of the research to date
suggests that as the cost paid by the user increases
compliance to the medication decreases. In the current
study, the average cost paid per prescription for the
antidepressant and the average cost paid per prescription
for all other medications will be considered separately. The
cost of other drugs was calculated separately from the cost
for the antidepressants so that we could get a better idea
of which direct patient costs were more likely to influence
compliance; the cost for the drug itself or the other drug
costs that a person was paying. Based on previous studies,
it was hypothesized that increased cost in each of the two
categories would decrease compliance.
A final objective of the current study was to evaluate
the problems and complications involved with utilizing the
Atlantic Blue Cross Database for compliance research.
3.2 Atlantic Blue Cross Database
A sample of prescriptions was taken from the database
of the Atlantic Blue Cross Prescription Drug Insurance Plan
based in New Brunswick, Canada. This database consisted of
any clients who used community pharmacies which utilize a
point of sale data system in Atlantic Canada (this includes
98~ of pharmacies; 2% of pharmacies have not yet switched to
a computerized system) .
Atlantic Blue Cross is utilized by individuals or
families who live in Atlantic Canada and, through work or
private means, have insurance coverage with Blue Cross.
Typically, subscribers on group plans might work with
agencies such as the federal or provincial governments,
universities, or other businesses. This excludes some low
income populations such as people receiving welfare and
seniors who utilize prOVincial drug plans. Therefore, the
results from this study are not necessarily applicable to
the general popula tion.
3.3 Study Desiqn
An historical prospective study design was utilized.
All beneficiaries of Atlantic Blue Cross who had at least
one antidepressant prescription filled during the
recruitment period of September 1995, were identified. A
total of 6389 individuals fitted ':he criteria IJf haVing an
antidepressant prescription filled during t.hat period. All
available records of all medications dispensed to each
individual during the period of the database; August 15,
1994 - September 30, 1996, were obtained from Blue Cross.
(Due to data storage problems, Blue Cross maintains records
on each beneficiary for a period of approximately 2 years.
Therefore, all data before August 15, 1994 was unavailable
"
for study.) The data was received from Blue Cross on
diskette.
Thus, approximately two years of data was obtained. As
can be seen in Figure 3.1, this time period was broken down
into two study segments. The period from Auqust 15, 1994
till February 15, 1995 was an initial screening interval.
Any individual who had a prescription filled during that
period was excluded. This was done to ensure that the first
prescription in the database was the first prescription for
that person. Six months is consistent with time intervals
used for initial screening in previous compliance studies
{Thompson et al., 1995; Jones et al., 19951. The second
study segment was the period between February 15, 1995 and
September 30, 1996, an interval of approximately one year
and seven months. Any individual who started antidepressant
treatment during this interval {as indicat.ed by their first
record} were included in the initial study cohor!:.
3.4 Ethical. Considerations
The data supplied by Blue Cross contained no
identifiers such as names or addresses which would allow the
researchers to identify specific clients. The pseudo-
identifiers, age and sex were prOVided for each subject. In
addition, each household or family was given a pseudo-
"
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Figure 3.1: Time Line For Study; All beneficiaries of Blue
Cross who had a prescription filled for an antidepressant
during the recruitment period were chosen. Any records for
these people which fell between 08/15/94 and 09/30/96 were
obtained. Any person who had a prescription for an
antidepressant filled during the initial screening phase ',",as
excluded from the study. Jl..ny person who started a course of
treatment during the study period (02/15/95 - 09/30/961 was
followed up to examine refill compliance.
identifier; a random four digit identification number. This
project was approved by the Human Investigations Committee
of Memorial University's Faculty at Medicine {see Appendices
3 and 4J
3.5 Database Management and Clean-up
Preliminary clean-up and analyses of the database
received was done in Microsoft Jl..ccess Version 7. The
database contained 14 different fields, each of which
contained specific information such as sex, date of birth,
dispensing date or trade name (see table 3.1). Several ot
the fields were not used in the study including the
'new/refill' and the 'total cost of the drug' fields. A
sample of the data can be found in Appendix 2.
3.5 1 Oriqinal Family/ Household Identification Number
The original data obtained from Blue Cross contained no
indi'J'idual identifiers. Rat-her, a four digit random nutn.ber
was used to identify all members sharing a family or
household policy. Because this number was random, it was
possible that several families may have received the same
identifier. In order to identify individuals, a unique
identifier had to be added to each person's set of records.
The family identifier was used as a partial indicator in the
attaching of a unique IO to each person,
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Table 3.1: Stmmary of Information Contained in 14 Fields of
Field Name
Family
Identi fica tion
Number
Unique ID
Counter
Date Of Birth Field
MI,
Dispensing Date
Quantity Dispensed
Days Supply
Total Cost of Dru
Cost of Drug to
Subscriber
Drug Identification
Number
Product Therapeutic
Class Code
Trade Name
Newi t'\efiii
Description of Information
Random non-exclusive 4 digit number which
identified members sharing a family polie
Added to records by researchers;
identified individual ceoole
The unique counter identified each
specific record"' for each person in the
database
Day/Month/ Year person was born
Sex of Client
Date on which drug was dispensed to clien·
Number of pills dispensed to person on a
particular dispensing date
Number of days that the medication supply
was intended to last client.
Total cost of drug paid b Blue Cross
Price paid by subscriber (deductible)
Standardized number which represents the
specific pill dispensed
Specific therapeutic class that drug
belonged to (i.e. antidepressant, lipid-
lowering etc. 1
Specific name of the dru dispensed
Indicated whether drug was a new
prescription or a refill
"' Record refers to one incident or drug dispensing for an
individual. Each time a medication was dispensed, a new
record was filled in with information entered into each of
the 14 fields.
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3.5.2 Adding a Unique 10 Number
A new identification (10) field containing a four digit
person identifier was added to each record in the database
that had similar characteristics. More specifically, if a
set of records all contained the same unique combination of
household ID number, sex and date of birth then a common
four digit number would be added to each record in the set.
This number would be unique to that particular combination
of family ID, sex, and birth date and would represent
mark all records for an individual person.
By using sex and age as indicators in addition to the
family identification number, the margin of error in
assigning new identifiers was reduced. In order for the
records of two different people to be combined as one
person, the records would have to have had the same random
Blue Cross four digit number, the same sex, and the
date of birth. It was impossible to distinguish the
incidences where records meeting the study protocol actually
belonged to two different individuals (as in the case of
twins). Hence, there may have been some error in adding the
individual identifiers.
3.5 3 Date of Birth Field
The database contained a 'Date of Birth' (DaB) field.
This information was used to aid in the identification of
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individuals as well as in the calculation of subject age.
The DOS field required data cleaning before the
information could be utilized. The date of births were not
always accurate in that an individual may have had t.wo
different dates of birth. A cleaning protocol was first.
developed in order to identify the records where the date of
births may have been inaccurat.e. All birth dates that did
not meet the cleaning protocol were left unchanged. The data
was cleaned using a series of steps. First, each record was
sort.ed on the basis of sex and four digit family or
household identifier. If two sets of records had t.he
identifier, t.he same sex, and slightly different dates of
birth then the records were inspect.ed further. If the
dispensing dat.es for both record sets were continuous (i. e.
the dispensing dates did not overlap between the two sets of
recordsl and the drug types (as ident.ified by t.he 'trade
name' field) were the same fer bet.h record sets, then ~he
records were considered t.o belong to one person and the
birth date was changed to the most frequent.ly recorded date.
If there were equal numbers of records wit.h each date then
the birth date was changed to the most recent dat.e.
Dispensing date and trade name were only checked if the
identification number and the sex were the same between two
records but the date of birth differed by one number in
either the year, month, or day field or if the birth dates
less than ten years apart. For example, if two record
sets had the same family Ie number, both specified 'male' in
the sex field, and the DOS's were slightly different
(08/08/73 and 08/09/73) then each of the records in the set
would be inspected. This process was done very
methodologically and records were only changed if they met
the specified criteria of having continuous dispensing date
and the same trade names. Records were left unchanged (i.e.
left as two separate people) if these criteria were not met.
Undoubtedly there was some error in this process but it was
a necessary procedure considering the errors in the
database. Most of the changes made were very obvious
mistakes. The birth dates may have varied by one or two
numbers in either the day, month, or year fields. The errors
were probably data entry problems at the pharmacy level and
may have been the result of a client utilizing different
pharmacies, each of which had different information on
him/her. In total, 2.01% of the initial birth dates were
changed.
3.5.4 M/F (Sex) Field
Sex of the subject was given as either a 'H' (Male) or
'F' {Female). A problem that was encountered in this field
the presence of a third sex identifier; 'X'.
Consultation with Blue Cress revealed that they had no
record of this field value_ An inspection of the birth and
dispensing dates showed that, in most cases, the dispensing
date was earlier than the date of birth suggesting that 'X'
may have signified a fetus. In all cases where an 'X'
existed in the data, the date of birth was in the year 1996.
There were only 15 identification numbers which contained
'X's in the sex field. Although these subjects were fiat
specifically eliminated because of this problem, all of
these records were eliminated in the final analysis because
they fell into one of the other exclusion criteria.
3.5.5 Dispensinq Date
Each record for each subject contained the date on
which the drug was dispensed. The dates given in the
'dispensing date' field were assumed to be accurate.
3.5.6 Days Supply
A major problem that was !:!ficounte:,ed with the Blue
Cross Database was that the 'Days Supply' Field, which
prOVided the number of days that a particular prescription
was dispensed for, was not a required field for the
pharmacies to complete. This field was critical to this
project because it was used in the calculation of any gaps
in treatment that may have existed for each subject. Several
patterns were picked up in the data that suggest that some
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pharmacies may have used default values for this field
instead of filling in the actual number of days that the
drug was supplied for. first, a number of records had '0',
'I' , '999', or '365' in the 'Days Supply' field. All people
with at least one record with either of these numbers in the
'Days supply' field were eliminClted from the analysis. In
addition, all other records with extreme numbers (>180
<10 days) in the 'Days Supply' Field were identified and
these records were reviewed individually and adjusted or
eliminated by a specified set of criteria. first, the
records with the extreme values were inspected in relation
to the other records for that person. If all of the records
had similar values in the 'Quantity Dispensed' field and
only several extreme values in the 'Days Supply' field then
the extreme records were changed to the more consistent
value of the 'Days supplyH field. for example, Table 3.2
depicts an instance for one person where all 'Days Supply'
records but one are for 30 days. In councer row 45014 , the
'Quantity Dispensed' field did not change but the 'Days
supply' did. It is assumed that this one extreme value was
the result of a data entry error. Inspection of the
dispensing dates also reveal that the person returned in 30
day intervals to refill the prescription further reiterating
that the 'Days Supply' for record 45014 should have been 30
67
Table 3.2: EJC!!!lPle of a Record Set for a Subject Wi th A
Incorrect Value In the 'Days SupplY' Row
'"
c.=_ DIN ....,...... Dl:SP DATE DRUG QTr DArS
1028 13289 740802 APO TRIMIP 15/02/95 30 30
1028 13293 740802 APO-TlUKIP 14/03/95 30 3D
1028 13296 740802 APO-TRIKIP 19/04/95 3. 3.
1028 13299 740802 APO-TlUKIP 23/05/95 3. ,.
1028 13305 740802 Al'O-TRIMIP 29/06/95 3. 3.
1028 28941 740802 Al'O-TRIMIP 31/07/95 3. 3.
1028 45014 7.1\0802 APO-TRIMIP 30/08/95 30 5
1028 65122 7.1\0802 Al'O-TRIMIP 28/09/95 3. 3.
1028 8U80 740802 Al'O-TRIMIP 30/10 95 3. 3.
1028 98077 740802 Al'o-TRlMIP 29/11/95 30 ,.
1028 113962 740802 Al'O-TRIMIP 29/12/95 30 3.
1028 130427 740802 APO-TRIMIP 31/01/96 3. 3.
1028 145767 7.1\0802 APO-TRIMIP 29/02/96 3. ,.
..
days. Records were only changed if these patterns could be
found in the data. Otherwise the values were left as they
3.5.7 Drug Quantity
The number of pills dispensed to a person on any
particular date was recorded in the quantity field. Blue
Cross required that the pharmacy complete this column each
time a drug was dispensed. No default values were identified
in this field. This field was essential in calculating the
variable, number of doses per day
3.5.8 Cost of Drug to Subscriber
Two cost fields were included in the database; the
total cost of the drug and the cost of the drug to the
subscriber. The total cost of the drug was not of interest
in this study and will not be discussed further. In
reference to the 'Cost to t.he Subscriber' field, the
percentage of the drug cost paid by the subscriber -raried
based on the benefit plan in which the person was enrolled.
This was of particular interest because it allowed for
comparisons of average cost paid per prescription per per:!ion
within each class of drugs.
"
3.5.9 Drug Identification Number (DIN), Trade Name, and
Product Therapeutic Class (PTC) Coda
These three fields of varying specificity provided
identification and information on the drugs dispensed to the
subscriber. The DIN was the most specific code. This is a
standardiz.ed number assigned to each different medicine
available. This number provides specific information
including such things as the trade name, route of
administration and dosage of the medicine. The trade is
less specific and does not prOVide specific information
about such things as dose. The most general identifier was
the PTe code. This code identifies the specific therapeutic
class of the drug. E"or example, all antidepressants have a
common PTe code.
These identifiers were used for several purposes. The
PTe code was used to identify all specific antidepressant
records which were then separated into a :"le'" table. The DIN
and t.rade names were used to identify the exact drug that.
the subject was dispensed. For the antidepressants, the
Canadian Drug Identification Code (CDIC) and the Compendium
of Pharmaceut.icals and Specialities (CPS) were used to
determine the generic name of each partiCUlar trade in
the database. Appendix 1 shows a complete listing of the
DIN, trade names, and generic names of the antidepressants
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found in the database
3.6 Exclusion of Subjects
46% of the initial study cohort (n=6389)
eliminated. Figure 3.2 depicts the number and chronological
order of exclusions and the associated reason for each
exclusion. A more detailed explanation for each of the
exclusions is provided in E"igure 3.2.
A number of people were excluded due to the incompleteness
or contamination of records in the 'Days supply' E"ield. Many
pharmacies entered default values (i.e. '0' ,'999', '1', or
'365') in this field because Blue Cross did not require that
the field be completed. In total, 1395 people were excluded
because of default values in this field.
Any subject who received antidepressants from more than
one class during the course of therapy was eliminated
because of the difficulty involved in doing interclass
comparisons on the study population as a whole !n- 998) .
This was particularly relevant for people who switched
between drug classes several times during the course of
therapy. It would have been extremely difficult to identify
true gaps in therapy for each class separately while
factoring in the possibility that a gap in therapy may have
been the result of a switch in class or a period when the
subject was actually taking an antidepressant from another
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1
Subject had a prescription
for more than ODe type of
trlC'O-clic or SSRI
1
Subject had antidepn::ssa.nt
Prescriptioofilled
duringinitia.lscrcco.ing
N,.IfIbuD(
S,.bin:tsRDff4UtUr(
Figure 3.2: Exclusion of Subjects. Depicts the initial
study cohort at the top of figure and shows the reason for
each exclusion, the nu..nber excluded for that reason and the
remaining number of people left. The chart flows in order of
exclusions. It is possible that subjects may have fit mare
than one of the exclusion criteria.
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class. An additional reason for excluding these subjects
from the study was that switching between medication classes
could possibly have impacted on compliance and thus acted as
a confounder.
All individuals who were on any antidepressant drugs
other than those falling into the tricyclic and SSRI classes
were excluded from the analyses because the focus of the
study involved only a comparison between these two classes
(n-JIS) .
Subjects were also excluded from the analyses if they
filled prescriptions for more than one type of medication
within a class at any time during the course of treatment
(n:229). The start of a new type of medication after
previously using another type in that class had potential
implications for observing the gaps in treatment. for
example, if a person started a new course of antidepressant
therapy while still having pills left from older
prescriptions, gaps in therapy would be masked because it
would be assumed that the person was using the old pills to
fill in the future gaps.
Several subjects were eliminated because they had
prescriptions filled during the initial screening period
between August 15, 1994 and February 15, 1995 (n:9). Any
other people that may have had prior prescriptions were
1]
elitn.inated earlier for other reasons.
Thus, the final pool of subjects included all people
who were not excluded because of inter- or intra- class
switching, because they fell into the first six months of
data, or because of data contamination. This left 3440
people in the study group, 1582 in the SSRI group and 1858
in the tricyclic group
3.7 Predictor Variables
A number of predictor variables were calculated using
various fields in the database. These variables are
described below. In addition, the calculation of these
variables as well as the fields that were used in the
calculation are summarized in Table 3.3.
3.7.1 Number of Doses Per Day
The number of doses per day was calculated for each
individual by dividing the quantity dispensed by the days
supply in c~de~ to deter:a.ine the apparent ..umber of doses
per day. We assumed that each unit of medication was taken
separately (i. e. that the prescription did not call for
taking more than one tablet per dose). This value was
calculated for each antidepressant record and an average was
found for all antidepressant records for that subject.
Table 3.3: Swmnary of Predictor Variables .. Calculation of
Predictor Variables and Database Fields Used in the
Calculations
PJlKD:ICTOR VAIlIABLK
Age
Sex
Antidl!pressant Cost
Other Cost
Concurrent
Medications
Number/Day
1996 - Year of Birt.h ~OOB'
H/F H/P
Avg Cost Per -Cost t.o Subscriber'
Prescription
(calculat.ed over
full treatment
episode)
Avg Cost. Per -Cost. t.o Subscriber'
prescript.ion
(calculat.ed for same
time as
ant.idepressant. cost.)
Number of different. - PTC code'
PTC codes in
subjects record in
first 45 days of
anti'd therapy
Number of pill ~Quantity Dispensed'
Dispensed / Number ~Days Supply'
of Days Supply
7S
3.7.2 Concurrent Medications
The number of concurrent medications was calculated by
counting the number of different PTe codes in a user's file
during the first 45 days of the antidepressant prescription.
Trade names were not used as indicators of the number of
other drugs a person was taking because they may vary for
the same type of drug. E'or example, during the course of
treatment with a particular medication, the pharmacist might
switch a person from an expensive brand name to a less
expensive generic brand of a drug. In this case, the trade
name would change even though the drug is the same as the
original. By using the PTe code as an indicator, is was
assumed that a person would only be taking one drug of a
particular type (i.e. antidepressant, lipid-lowering etc.)
at anyone time. Thus, a count of the number of different
PTe codes was actually a count of the number at di fferent
therapeutic classes of dru.gs that the subject ·....as issue.::!
drugs from during the first 45 day interval.
A uniform 45 day time interval was used so that the
nU.lllber of concurrent medications could be compared bet:ween
subjects. Because treatment duration varied between people,
there would have been a greater chance that subjects on the
antidepressant medication for a longer interval would have
taken more concurrent medications. Thus, a count of the
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total number of other medications during the entire
antidepressant episode for each subject would have been
dependant upon duration. To ensure that the measure was
independent of duration, only those medications dispensed in
the first 45 day period of the antidepressant episode (Le.
first dispensing date for an antidepressant + 45 days) were
count.ed.
3.7.3 Age and Sex;
Age was calculated for each subject by subtracting the
year that the person was born trom 1996. Days and months
not taken in account when calculating the age.
3.7 4 Cost to Subscriber
The cost to the subscriber was broken down into two
variables; the cost paid per prescription for
antidepressants and the cost paid per prescription for other
drugs. The cost for antidepressant. therapy was calculated as
the average cost paid per prescription during the treatment
episode. The average cost paid for other drugs was
calculated for the time period during which the subject was
dispensed an antidepressant medication. Thus, the only drug
costs for other medications included in the calculation of
the average cost paid for other drugs, were those where the
associated dispensing date was between the start. and end-
date for the episode of antidepressant therapy.
n
3.8 Class Identification
Many of the analyses were also done separately for each
class to reduce the variability due to intra- class
differences. In addition, separate analyses allowed us to
look at trends within each class.
Each antidepressant trade name in the database was
classified into a specific class and type within that class
(generic) on the basis of recolI1ll1endations from several
including the Canadian Drug Identification Codes
(CDIC), the Compendium of Pharmaceuticals and Specialities
(CPS}, Dr. T. Kara, and MS. Audrey Fultz of The Pharmacy
Resource Centre (Memorial University of Newfoundland). All
antidepressant records were first identified based on a
COlI1ll1on PTC code; 281604. In total, there were 163 different
trade names included in the data. These were each divided
into one of 6 classes inclUding tricyclics, selective
serotonin re-uptake inhibitors ISSRI' 5), serotonin-
norepinephrine re-uptake inhibitor (SNRI), heterocyclics,
monoamine oxidase inhibitors (MAOI' s), and atypical
antidepressants. A complete list of each trade name, the
associated DIN, class, and generic name within each class
can be found in Appendix 1.
"
3.9 OUteome Jleasure:llU!Dt
Several outcome measures were used including percentage
of days wit:hout: medication (i.e. percentage of non-compliant
days), t:ime lin days) till a first non-compliant gap, and a
comparison of early medication stoppers to those who did not
stop taking their medications. Detailed descriptions of the
outcome measures as well as the underlying assumptions that
were made in terms of treatment episodes are described
below.
3.9 1 Finding Gaps In Treatment
In order to examine patterns of refill within a
treatment episode it was necessary to identify gaps in
treatment. This calculation was used in both the percentage
of non-compliant days and the time till a first non-
compliant gap outcome measures. A gap was defined as any
period during treatment when a person did not have any
medication in hand, based on the int'ormation in the
database.
In order to calculate the treatment gaps several pieces
of information were necessary. First, the dispensing date
for the medication was needed. Second, the number of days
that the medication was dispensed for was critical for
calculating the end date or estimated stopping date when the
medication from that particular prescription should have
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been completely consumed. The end date, then, was calculated
by adding the number of days that the medication was issued
tor to the original dispensing date. This end date was then
compared to the next chronological dispensing date in the
subject's records. For example, it a person filled a first
prescription for 30 days and did not till a second
prescription until 10 days after the end date for the tirst
prescription, then a 10 day gap in treatment would exist.
However, the calculated gap between the end date of one
prescription and the dispensing date of the next
prescription, did not necessarily represent a true gap in
treatment. For example, if a person filled two prescriptions
on the same day, each tor a 30 day supply of pills, negative
30 would appear as the difference between the end date ot
the first prescription and the dispensing date of the second
prescription. However, assuming that the person filled the
third prescription on time (i.e. 60 days after the first
dispensing date) then the difference between the end date
for the second prescription (filled on the first day) and
the third prescription would be .. 30. This would occur
because the end date for the second prescription would be
the same as the end date for the first prescription because
both had the same dispensing date and the same value in the
'Days Supply' field, 30 days. Thus, the difference between
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the second end date and the third dispensing date would
create an artificial gap in the data. This problem would
occur on any occasion when a person returned to the pharmacy
early (i.e. before t.he end date for the prescription) to
obtain a refill. Therefore, negative 'gaps' in the data had
to be carried forward to cancel out fut.ure posit.ive gaps. A
negative number indicated that a person had 'X' many days of
extra pills on hand.
The problem of artificial gaps was remedied by starting
a running total of the calculated gaps for each person. Any
negative gaps would be added into the next (chronological)
positive or negative gap. However, when the running sum
became positive then a real gap in t.reatment had occurred.
At this point, the subject, according to t.he data, could not
have had extra pills on hand because all negative refill
days were accounted for. Each time a positive number
occurred in t.he running total, it was reset to the value of
the next gap as calculated from the end date and dispensing
date. Thus, the t.rue gaps in treatment that occurred were
the positive numbers that occurred in the running sum that
calculated from the original gap calculation. The
negative numbers that occurred in the running sum column
were an indication of the number of extra days of pills that
a subject had on hand at that point in time.
8'
3 _9.2 Identification of Treatment Episodes
A t.reatment episode was defined as a period of
cont.inuous treatment with the antidepressant. Because
information on treatment duration or reasons for stopping
treatment were available from the data, it was necessary to
infer that a particular treatment episode had ended based on
a specific algorithm. A treatment episode was considered to
have ended when a gap of 90 days or greater occurred between
two consecutive prescriptions. Thus, any two consecutive
prescriptions fills separated in time by less than a 90 day
gap in treatment were classified as part of the same
treatment episode whereas any two consecutive treatment
fills with a gap greater than 90 were classified as separate
treatment episodes (see figure 3.3). Simon et a1. (1995) also
used a 90 day or greater gap in treatment as t.he signal that
a treatment episode had ended. This relatively long interval
was chosen in order to exclude any records for a subject
t.hat may have occurred after a recent treatment failure _ Any
subject. might have had more than one treatment episode but
only the first t.reatment episode was utilized in this study.
3.9.3 Calculation of Treatment Duration
for the percentage of non-compliant days measure, it
was necessary to calculate overall treatment duration for
the episode of treatment. This was accomplished by
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Episode I
IS day Rx
Case I +------+ I
JO day Gap
4-----+ .., ..+------;---....Cue 2:
20 day Rx 92daypp
..~I(end)
Figure 3.3: Identification of Different Treatment
Episodes, Rx = the dispensing date for the prescription;
Rx (End) = the end date for a prescription; In Case I, two
prescriptions were dispensed. The Gap between the end date
of r:he firsc and che scarr: dar:e of the second was 30 days.
Thus both prescriptions would be considered part of the same
treatment episode. In Case 2, two prescriptions were
dispensed. In this case, the gap ber:ween the end date for
the first and the start date of the second was 92 days _ Thus
the two prescriptions were placed in different treatment
episodes.
subtracting the first dispensing date in the treatJnent
episode from the final end date for chat episode. The final
end date was calculated by adding the dispensing date of the
last prescription in that episode to the number of days thac
the prescription was filled for ..lkcordingly, the end dace
was the estimated stopping date on which the last
prescription fill of the episode should have been complecely
consumed and would have been the final date that a subject
would have had any medication on hand (according to Blue
Cross records). Therefore, treatment duration, as was used
in several of the outcome measures described below, was
actually the duration of the full treatment episode.
3.9.4 Percentage of Non-compliant Days
This outcome variable measured the percentage of
medication free or non-compliant days during the treatment
episode. The percentage of days that a person was without
medication during the first treat!!l.2nt 2pisode 'lias ca!.culat~d
by summing the number of positive gaps during treat.ment and
diViding it by the treatment duration.
The function of the statistical analysis done on this
variable was to determine whether or not the predictor
variables could predict the extent of non-compliance.
It should also be noted that all people who filled only
one prescription for an antidepressant and then stopped
..
(Le. did not return for a refill) were also not included in
this analysis because they would not have had any
discernible gaps in treatment. Individuals who stopped
medication after only a short interval or after one
prescription were considered in another analysis which
specifically compared medication 'stoppers' to those who
continued pass a specified period.
3.9.5 Early Medication Stoppers versus Continuers
In the previous outcome measure, compliance was viewed
from the perspective of gaps in treatment. Very little
emphasis was actually placed on the duration that
individuals remained on treatment. A second outcome measure
was used which was similar to that used in study by Thompson
et al. (1995) on lipid-lowering medications They classified
individuals who filled one prescription as stoppers as
compared to those who filled more than one prescription who
were deemed treatment continuers. In the curr~nt study
stoppers were defined in two ways, (1) those who filled only
one prescription and (21 the total duration of
antidepressant use.
Subj ects .....ho filled only one prescription were
identified as having only one antidepressant record in the
database. These subjects were compared to the remainder of
the sample who had more than one prescription filled.
"
In terms of duration of use, medication users were
classified as stoppers if their total duration on the
medication was less than a critical lenqt.h of time. Two
critical stopping times were used, 30 and 60 days. In most.
cases subjects who filled only one prescription would have
fallen into these categories. It should be noted however,
that in some cases several prescriptions may have been
filled before this duration was reached. To clarify this
scenario further, if the duration was less than or equal to
30 or 60 (depending on the analysis) then the subject was
classified as a medication stopper. If the total duration
for a subject was greater than the specified critical time
then the person was considered a non-stopper. (see Fiqure
3.4)
The Blue Cross database utilized in this study did not
have standard refill times. Hence, it was possible that the
first prescription may have ranged in duration from as
little as 10 days to as high as 100 days. By setting
specific duration cutoffs (30 or: 60 days), we were able to
look at all people who stopped at approximately the same
time As was discussed in the introduction, the assumptions
of 30 and 60 days were made based on two criteria; outcome
measures used in previous studies and theoretical ideas
concerning compliance to antidepressant medications.
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28 Days
+
""I(S12rt)
+
""I
""I(End)
(S12rt)
....,lb
+ Rxl (End)
Last Prescription
S8 Days
180 Days
..
Rd(End)
Last Prescription
Figure 3.4: Classification of Subjects as Stoppers or Non-
stoppers based on 30 and 60 day assumptions _ Rx (Start) :0
Dispensing date at first prescription in episode; Rx (End) -
End Date of last prescription in episode.
In Case 1, the treatment duration was 28 days. Thus,
this subject would be classified as a stopper under the 30
and 60 day assumptions.
In case 2, the treatment duration was 58 days. This
subject would be classified as a stopper under the 60 day
assumption but as a continuer under the 30 day analysis.
Finally, in case 3 , the treatment duration is 180
days. This subject would be classified as a continuer under
both assumptions.
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3.9.6 Time Till First Non-compliant gap
The duration of time that a person remained on the
antidepressant before they became non-compliant was compared
among levels of the predictor variables. For the purposes of
this study, a non-compliant gap was defined based on two
different assumptions or definitions; {ll that a 15 day gap
in treatment represented a non-compliant episode and (2)
that a 30 day gap in treatment represented a non-compliant
episode (see figure 3.5).
It was necessary to define what magnitude or gap size
would be considered a non-compliant period. In the
previously discussed percentage of non-compliant days, the
compliance measure was a continuous variable. Thus, it was
appropriate to view smaller treatment gaps as part of that
continuum in order to get a full picture of non-compliance.
In contrast, in this measure, the goal was to identify the
first significant non-compliant episod.e. It ".-las assumed that.
smaller gaps in treatment represented lesser magnitUdes of
non-compliance. Gaps of 15 and 30 days were used because
they represent more significant gaps in treatment and thus,
are more significant periods of non-compliance. Thompson et
al. (1995) looked at duration till stopping treatment and
used 30, 60 and 90 day assumptions to ascertain whether or
not the subject had actually stopped medication. In the
..
I JO day tTeatmeat 1
+ ..-
Rx t Rxl
(Stut) (E1ld)
JOdaVpp
..
IW
+ "..-Rx 1 Rxt R12
(Stan) (Elld)
l~
... ..-
""2 IW
(End)
Fiqure 3.5: Calculation of survival duration till first
non-compliant episode for >:15 and >:30 day assumptions.
Rx (Start) - first prescription in episode; Rx (end) - end
date for each individual prescription; Rx - dispensing date
for prescription.
In Case 1, a treatment episode of 30 days was followed
by a 30 day gap in treatment. Thus, the survival duration
till the first gap is 30 days. This is true for both the
>:15 day and >530 assumptions.
In case 2, a 30 day treatment episode is followed by a
5 day gap, another 30 day treatlnent episode, and then a gap
of 15 days. This 15 day gap would fulfil the >=15 day
assumption not but the >=30 day assumption. Thus the
survival duration for the >=15 day assumption would be 65
days (30 + 5 + 30 days). The survival duration by the >=30
day assumption would be the duration until the first gap
>-30 days.
"
Thompson et al. (199S) study, the time intervals were longer
because the authors were attempting to ascertain whet.her
the subject stopped medications. In t.he current study, the
gaps are considered non-compliant periods or breaks in
treatment and do not represent the stopping or discontinuing
of t.reatment.
3.10 Data Analysis
Data was analysed using SPSS Version 7.1. The purpose
of the data analysis was to evaluate the st.udy objectives.
Additional analysis were used to describe the sample in
terms of utilization patterns.
A number of frequencies and cross tabulations "'ere
done t.o describe pat.terns of ant.idepressant utilization in
terms of class use, and t.he other predictor variables;
demographic (age, sexl, medication complexity (number of
pills per day, and number of concurrent medications), and
the cost to the subject.
Each of the three outcome measures; percentage of non-
compliant days, the early medication stoppers versus
continuers and the time till a first non-compliant gap
measure ",ere analyzed separately in terms of the appropriate
objectives. Descriptive statistics were done in order to
describe the extent of non-compliance (objective 1) as well
to compare compliance between the SSRI's and Tricyclic
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antidepressants (objective 2). Descriptive statistics,
regression analysis, and survival analysis were utilized to
look at the changes in compliance at various levels of the
predictor variables (objectives 3-5)
3.10.1 Percentage of non-compliant days
Frequencies and cross tabulations were used to describe
the sample in terms of the percentage of non-compliant days.
Frequencies were calculated for various groupings of the
percentage of non-compliant days. These statistics allowed
us to get a picture of non-compliance as measured by the
percentage of non-compliant days (objective 1) and to see
how the percentage differed between the SSR!' sand
tricyclics (objective 2). The mean percentage of non-
compliant days was found for each level of the predictor
variable (objectives 3-5)_
A mUltiple regression analysis was per fanned to
ascertain whether differo:nces in class or in levels of the
various predictor variables could account for any of the
variance in the percentage of non-compliant days. Because of
the large number of predictor variables used, a backwards
stepwise regression was utilized. This analysis regressed
all of the variables against the outcome measure and
eliminated variables at each step in the regression if they
did not meet the standard SPSS specified inclusion criteria
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for elimination of variables at each step in a backwards
regression (p= .10) .
3.10.2 Stoppers Versus Continuers
The proportion of the sample stopping after one
prescription or after either 30 or 60 days was calculated in
order to determine the magnitude of the problem of
discontinuing medication in the sample.
Frequencies and percentages of users in each group
(stoppers or continuers) were compared to determine the
extent of non-compliance as indicated by the number of
stoppers (objective 1). This was also done for each class
that comparisons could be rn.ade between classes (objectiv'!!:
2). Means and confidence intervals were calculated for all
levels of the continuous predictor variables; age,
number/day, concurrent medications, and cost. :requencil!!s
and percentages were calculated for the categorical
variable, sex {objectives 3-5).
3.10.3 Time Till First Non-compliant Episode
Survival analysis was utilized to determine whether
survival curves differed between classes (objective 2) and
among various levels of the predictor variables (objectives
3-5). A life tables analyses was chosen instead of the
Kaplan Meier approach because of the large numbers involved.
The first analysis was strati fied by class. This was done in
"
order to determine whether there was a difference in the
survival curves between classes. E'urther analysis were done
separately for the tricyclic and SSRI classes and were
stratified by various levels of the predictor variables.
Overall and Pairwise comparisons of survival curves were
done for each analysis using the W'ilcoxan (Gehan) statistic.
The use of multiple pairwise comparisons necessitated the
reduction of the significance levels for a number of
comparisons. This was done by dividing the standard a level
of 0.05 by the number of pairwise comparisons done. A table
documenting these calculations can be found in the results
section.
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4 RESULTS
4.1 General Utilization Patterns
4.1.1 Class Breakdown
The antidepressants were divided into 6 classes based
upon recommendations from several sources (Krogh, 1994;
Arana et al., 1987; Bernstein, 1995). The classes included
the tricyclics, the SSRI's, the MAOI's, the heterocyclics,
the SNRI's, and the atypical antidepressants. Appendix 1
shows the DIN, trade name, generic name, and associated
class for each medication available in the database.
The breakdown of people into class of antidepressant
use presented difficulties because of the number of people
who switched between classes of medication. 1380 people out
of the total sample (n=6389) had prescriptions for drugs
from more than one class. This number is larger than that
given in Figure 3.2 because it represents the entire sample
befe=e an'! ether exclusions. In fiqure 3 _2, a number of
subjects (n=1395) had already been excluded because of
default or missing values in the 'Days Supply' field which
was the first exclusion done _ Some of the people who were
excluded in this initial exclusion had prescriptions from
more than one class.
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A person was counted in each class that s/he had a
prescription for. This resulted in a total 'N' which was
greater than the actual 'N'.
Table 4.1 shows the number of people who had a least
one prescription from each of the classes before any
exclusions. As can be seen, the tricyclics and the SSRI
classes were the most commonly used classes.
4.1.2 Demographics and Patient Treatment Characteristics
After all exclusions (see section 3.6), the final
sample contained 3440 individuals. Table 4.2 shows a
breakdown in terms of the variables utilized in the study;
age, sex, average cost per prescription (antidepressant and
other), number of concurrent medications, and number of
doses per day. Percentages for each class given within
each level of the demographic variables (age, sex) or the
patient:' s treatment characteristic. O~Te~3.!!, =. slightly
higher percentage of the sample was using medication from
the tricyclic class than the from the SSRI class (54~ and
46% respectively).
The sex ratio of males to females was 1: 2.1
respectively. This ratio was approximately upheld within
each class.
"
Table 4.1: Numb&.r of People who had at least one
prescri.ption filled from. each of the Classes of
Antidepressants
Antidepressant Class
Tricyclic
SSRI
MAO I
Heterocyclic
SNRI
At ical
Total"
Number of People who had a
least one prescription filled
3360
3413
367
4072.,
240
8068
1 Class = 5009
2 classes "" 2254
3 Classes "" 639
4 Classes"" 140
5 Classes "" 20
X 6 Classes - 6
TOTAL - 8068
"The total over-counting can be broken down in terms of the
number of classes that each individual had a prl!:scription
from.
Total Over-count.ing;
* of People;
5009
1127
213
35
4
1
Table 4.2: Frequencies and Percentaqes of Users in Terms of
Demographic and Patient Treatment Characteristics
Variable SSRI Tricyclic Total
Sex
Male 517 (32.7%) 593 (31.9%) 1110 (32.2)
Female 1065 (61.3%) 1265 (68.1%) 2330 (61.8)
""e
<-20 Years 51 (3.2'!) 10 (3.8%) 121 (3.5~)
21-35 Years 265 (16.8%) L14 (9.H) 439 112.7%)
36-50 Years 801 (50.6%J 194 (42.7%) 1595 (46.4)
51-65 Years 410 (25.9%) 102 (37.8%) 1112 (32.3%)
>65 Years 55 (3.5%) 118 (6.3%) L13 (5.H)
Concurrent
Medications
0 415 (26.2%) 381 (20.8'ti:) 802 (23. 4~)
L 424 (26.8'!) 470 (25. 3~) 894 (26.0"':)
2 305 (19.3%) 311 (20.3%) 682 (19.9'.l!)
3-4 3LO (19.6%) 391 (21.4%) 101 (20. S~)
>:5 128 18.!'!) 221 (12.2%) 355 (10.2%)
Average Cos t for
All Other
Pres=iptions
654<-$4.00 (41.3~) 685 (36.9ii;) 1339 (38 .9~)
$4.01-8.00 111 145.3~} 865 f46.6·a l lSaZ f4S.9"!
>=$8.01 211 ( 13.4%) 308 f16.5%1 5L' f15.2·~1
Average Cos t for
antidepressant
<=$4.00 262 (16.6%) 944 (SO.8ii;) 1206 (35.0%)
$4.01-8.00 843 (53.3%) 135 (39.6%) 1518 (45.9%)
>=$8.01 411 DO.B) L19 (9.6i:) 656 (19.H)
Number of Doses
Per Day
1 1041 (65.8%) 536 (28.8%) 1577 (45.S'!)
>1 541 (34.2%) 1322 {11.2%} 1863 (54.2%)
Totals 1582 (46.0%) 1858 (54.0%) 3440 (lOOi)
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The mean age for the sample was 46.75 years (95!'CI;
46.33-47.17). 79!' of the sample fell in the '36-50' and '51-
65' age groups. The '<220' and '>65' age groups had the
smallest percentages of subjects (3.5 and 5.1~
respectively). The percentage of people within each age
group did differ somewhat by class. In the younger age
groups, '21-35' and '36-50', the percent.age of people on
SSRI's was slightly higher. In contrast, in bot.h the '51-65'
and '>65' age groups, the t.ricyclics had higher percent.ages
t.han did the SSRI' s .
In terms of concurrent medicat.ions, the mean for t.he
sample was 1.99 (9S'!CI; 1.92-2.05). 23.4% of the sample were
taking no concurrent medications, as opposed t.o 76.6% of t.he
sample who fell into the '1', '2', '3-4', and '>=5' groups.
The largest. percentage of people fell into the '1'
concurrent. medicat.ion group (26.0~). The number of
concurrent medication did not vary great.ly among classes.
Small percent.age differences exist.ed between all concurrent
medication groups. The greatest differences were bet.ween the
lowest (0) and t.he highest (>=5) groups with the SSRI's
having slightly higher percentages of users in the lowest
group and the tricyclics in the highest group.
The mean average cost paid per prescription for other
drugs that an individual was using was $4.68 (95%CI; 4.57-
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4.19). 84.8% of the sample were paying less than or equal to
S8.00 per prescription. Only 15.2% of the sample were paying
more than S8.00 per prescription. This breakdown did not
vary greatly between classes.
The mean average cost paid per prescription for
antidepressants reflect the price differences that exist
between the two types of medications (i.e. the SSRI's are
more costly). The mean cost per prescription for the SSRI's
was 51.19 (95~CI; 56.93-1.44) as opposed to 54.37 (95%CI;
~4.24-4.49) for the tricyclics. SO.8'! of those on tricyclics
fell into the <0:$4.00 group as opposed to 16.6':! in the SSRI
group. In contrast, 30.2! of those taking SSRI's fell into
the >-8. 01 prescription group as opposed to 9.6% in the
tricyclic group.
4.2 Non-compliance OUtcome Measurement
4.2.1 Percentaqe of Non-compliant Days
Pe=.::entage of ncn-ccl:lplian:: days ..as calculated by
dividing the days without medication by the total duration
for the treatment episode multiplied by 100. The total 'N'
involved in this measurement was less than the total 'N' for
the sample. Three hundred and twenty seven subjects were
excluded from the frequency analyses because they had only
one prescription in the database and thus had no discernible
gaps in treatment between refills. The total 'N' tor the
"
frequency analyses was 3113. The mean percentage of non-
compliant days for these 3113 subjects was 8.4!: (95; cr;
1.9-8.9) .
A mUltiple regression analysis was performed in order
to ascertain whether class and the other predictor
variables; age, sex, number of concurrent medications,
number of doses per day, and the two cost variables had an
impact on extent of non-compliance. This analysis was used
to determine whether the predictor variables could predict
the extent. of non-compliance among subjects who exhibited
some level of non-compliance. The analysis involved only
those subjects who had a percentage of non-compliant days
greater than zero (n-1454). Thus all subjects who had no
gaps in treatment (percentage of non-compliant days = O'!!)
not included (n=1659). Because the group with a
percentage of non-compliant days of zero was so large it
skewed the distribution to a point that regression analysis
could not have been utilized. Even after exclusion of che O!:
group, the values were still not normally distributed. Thus,
the log of each data point was found in order to make the
data suitable for analysis by parametric regression
analysis. The distribution of the original and
logarithmically transformed data can be found in Appendix 5.
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4.2.1.1 Extent of Non-comp1iance/ Tricyclics Versus
SSRI's; Tables 4.3 and 4.4 present the distribution of
patients by percentage of non-compliant days. For both the
tricyclic and SSRI classes, the largest percentage of all
users (55.4% and 50.9% respectively) had no non-compliant
days between refills. Also, addition of the percentages in
the first five rows of the table shows that as'! of all SSRI
and S5. 51! of all tricyclic users had less than or
equal to 25~ of days without medication. That left only
12.0% of the SSRI sample and 14.5% of the tricyclic sample
who had more than 25~ of days without medication. As can be
seen from these numbers, the extent of non-compliance did
not vary a great deal between the SSRI and tricyclic
classes. Class was also included as a predictor in the
multiple regression that is presented later in sect.ion
4.2.1.2.2 of the results. Class was not a significant
predictor of the extent. of non-compliance among users with a
percentage non-compliance greater than zero.
4.2.1.2 Predictor Variables; Table 4.5 shows the mean
percentage of non-compliant days for each level of the
predictor variables stratified by class. In the following
commentary, the only differences that were described were
cases when the mean percentage of non-compliant days between
different variable levels were
'0'
Table 4.3: Distribution and Percentage of Users by
Percentage of Non-Compliant Days for Tricycl.ics
Percentage of
Days Without
Medication
O.
<-5%
>5 and < 10%
>10 and <=151!
>15% and
<=25%
>25 and <-50%
>50 and <-75%
>75%
Total
Frequency
917
144
143
82
128
209
29
2
1654
Percentage of
Total (t)
n-1459
55.5
8.7
8.6
5. a
7.7
12.6
1.8
0.1
100
Table 4.4: Distribution and Percentage of USQrs by
Percentage of Non-Compliant Days for Subjects taking SSRI's
PQrcentaqa of
Days Wi thou t
Hedication
O.
<""5%
>5 and < 10%
>10 and <-15%
>15% and
<-25%
>25 and < 50%
>50 and <-75%
>75%
Total
Frequency
742
151
130
116
144
162
14
a
1459
Percentage of
Total (%)
n-1459
50.9
10.3
8.9
8.0
9.9
11.0
100
102
Table 4 5: Kea.n Percentages of Ron-compliant Days by Patient
Treatment Characteristic (Strt.tiUc4 by Class)
Variable
Sex Hale
Pemalt!
Age (Years)
<.20
21-35
36-50
51-65
>.5
Ccncu.rr~t
MedicatioDs
o
1
2
3-'
>.5
Dose. Per Day
1
>1
Aver Cost for
Other Drugs
<.$4.00
$4.01-8.00
>.$8.01
Aver Cost for
anti'd
<.$4.00
$4.01-8.00
>.$8.01
SSRI ..an Percentage
of Kon.cOl!pliant Day.
(\:) (95\: Confidence
Interval, N)
.LQi. (6.99-9.13)n.477
.a......u. (7.53-9.14)n_982
L.U(6.50-13 .17)0..44
~(7 .4210.74)0.237
.a.......ll(7.23-9.02)0:739
1.....ll(6. 57-9.09) 0.386
Ln.(4 .25-11. 41) n.53
~{8.69-11.3)n",,376
~{7 .11-9 .66) n=385
1....J:I.(6. 32-9.22) n",283
~(5 .53-8 .31)n=296
.6.......ll (4.67-8.56) n.119
~(7 66-9.27)n.944
1.......B.i.(6 77-8.92)0·515
L2.2(6. 82-8.73) n ..597
.8.........i.i. (7.45-9.42) 0-667
I~(7 .17-10 .89)n..195
9......1.a.(s. 26-8.30) n.244
~(6.92-8.56) n.780
I~(8.64-11.29)n_435
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TriCYClic~
PercltPtage of Ron-
compliant nays (%)
(95% Confidence
:Interval, N)
..e.......ll{7.19-9.62)n.519
,Lti(7. 83 -9 .48) n.1135
~(9.53-18.10)n",54
.z......ll (5.93-9.93)n.140
~ (7.59-9.71)n=706
.a.......s.s. (7.73-9.97)0=644
.L.H (2.57-6.9510..110
ll....J.2.(9. 48-12.97) n:329
.!.Q.......J.6.(8.86-11.87 0=407
1.........2..2.(6.28-9.04) 0:342
9........U.(5.44-8.00)n"'362
.s.........Il.(4 .11-7.33) 0=214
L,ii(5. 32-7.61) 0=442
~(8 .52-10 .18)n.. 1212
.a......a2(7 75-10.00)n=606
.8.........Q.2(7 09-9.04)n.770
.2.........l..6(7 55-11.17)n..278
.2..:....J...2(8 .33-1.0 .37)0=831
L...2.6.(6 74-8.78) 0=658
L.,ll(5 93-9.91) n,.165
different and the corresponding 95~ confidence intervals of
the mean did not overlap.
4.2.1.2.1 SSRI Group; Among the SSRI users, there was
little difference in the percentage of non-compliant days
between males and females. There were however, differences
between the age groups. As age increased, mean percentage of
non-compliant days decreased. The difference in means was
greatest between the '<=20' and '50-65' age groups (9.84~
and 7 .82~ respectively). It should be noted that these
differences Oiere not large and in all cases, the confidence
intervals for the means over-lapped between the groups.
In terms of medication complexity, the mean percentage of
non-compliant days decreased as the number of concurrent
medications increased. The difference in the means was
greatest between the "0" and "3-4" and the "0" and '>=5'
groups. These differences were complemented by non-
overlapping confidence intervals suggesting that a real
difference in the means of these groups does exist. A
difference in means existed between those taking one pill
per day and those taking more than one pill per day (8. 46!:
and 7.84% respectively). However, the confidence intervals
between these groups overlapped each other.
,..
The mean percentage of non-compliant days increased as
the cost for the other medications that a person was taking
increased. However, the confidence intervals between these
groups overlapped. This trend was evident for the cost of
the antidepressant medication as well. More specifically,
level of cost of the antidepressant. increased t.he mean
percentage of non-compliant days also increased. This
difference in mean non-compliance was greatest between the
group paying <=$4.00 and the group paying >::$8.01
evidenced by non-overlapping confidence intervals.
4.2.1.2.2. Tricyclic Users; Among the tricyclic users,
there was very little difference in the sexes in terms of
percentage of non-compliant days. Age differences were
evident between the '<20' and the '>65' groups 113.82'! and
4. 76~ respectively). The confidence intervals between these
two groups did not overlap.
As the number of concurrent medications increased the
mean percentage of non-compliant days decreased. Significant
differences, as evidenced by non-overlapping confidence
intervals, existed between the '0' concurrent medications and
the '2', '3·-4' and '>::5' groups. In terms of the number of
doses per day, people taking one dose per day had a lower
mean percentage of non-compliant days as opposed to those
taking more than one dose per day (6.46~ and 9.35%
10'
respectively). Confidence intervals for these means did not
overlap.
No pronounced differences in mean percentage of non-
compliant days existed for either the average cost of other
or of antidepressant medications.
4.2.1.2.3 Reqression Analysis; In a mUltiple regression
analysis with percentage of days without medication as the
dependent variable, none of the predictor variables were
siqnificant predictors of the extent of non-compliance among
subjects who exhibited some level ot non-compliance (i.e.
percentage of non-compliant days > 0). In a backward
regression model initially involVing the predictor
variables, class, sex, age, average cost for other
medications, average cost for antidepressant medications,
number of concurrent medications, and number of medications
per day, very little of the variance in the percentage of
non-compliant days measure was accounted for by the
predictors in the final model. (R~ - .011, F(2, 14531 .,
13.47, P > .05). The final model contained only two of the
predictor variables; number of concurrent medications and
number of doses per day. The respective Beta's were -0.097
(5E; 0.016) and 0.099 (5E.; 0.025). The other predictor
variables were eliminated in earlier steps of the model.
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4.2.2 Early Stoppers Versus Continuers
Based on several definitions of 'medication st.opper',
t.he sample was divided into dichotomous groups of either
early medication stoppers or medication continuers. f'irst.,
all individuals who had only one prescription filled for an
antidepressant were classified as early medication stoppers.
Second, all individuals who had a total t.reatment duration
less than flJ 30 days or (2) 60 days were also classified as
medication stoppers. Separate analyses were done for each of
these assumptions.
4.2.2.1 Extent of Non-Complh.nce; Table 4.6 summarizes
the numbers of subjects who fell into each group for each of
the three assumptions. The number of st.oppers was quit.e low
for each assumption with the greatest percentage of st.oppers
in the 60 Day assumption (11.4!!).
Table 4.6; Frequencies and Percentaqes of Sample Who Fell
Into Either the Stoppers or Continuers Group by the three
definitions of stoppers
Assumption
One Prescription
One Pres.
> One Pres.
30 Day
<=30 Days
>30 Days
60 Day
<=60 Days
>-60 Days
Number of Subjects
(N""'3440)
327
3113
279
3161
391
3049
107
Percentage
(0)
9.5
90.5
8 .1
91. 9
11
88
4.2.2.2 Tricyclics Versus SSRI's; Table 4.7 shows the
percentages and frequencies for individuals in each group
within each assumption stratified by medication class. The
percentage of tricyclic users who stopped was slightly
higher than the percentage of SSRI users who stopped
medication. This pattern was true for all assumptions.
Table 4.7: Frequencies and Percentaqes (Within each cell) of
Individuals in each qroup by the assumption and class
Variable One
Prescription
Class 1 >1
Pres. Pres
30 Day
Assumption
<-30 >30
Days Days
60 Day
Assumption
<-60 >60
Days Days
SSRI 123 1459 106
(7.0l (93.0) (6.7)
Tricyclic 204 1654 173
(11.0) (89.0) (9.))
1476 152 1430
(93.9) (9.6) (90.4)
1685 239 1619
(90.7) (129) (87.1)
4.2.2.3 Predictor Variables; The relatively small number of
'stoppers' as compared to 'continuers' made analyses using
this group very difficult. Logistic regression was the
method of choice, but due to the small nwnbers in the
'stoppers' group, this test could not be used. Instead, the
data was described using means, frequencies, and
(08
percentages. Means and confidence intervals were calculat.ed
for the continuous predictor variables (age,
number of concurrent medications, number per day, and both
cost variables) fo::' each class. frequencies were provided
for t.he nominal variable,
4.2.2.3.1SSRI Users; for the sample of SSRI users, the mean
age of 'stoppers' was less than for the 'cont.inuers' and the
confidence intervals did not. overlap between the 'stoppers'
and 'continuers' group. This was true for all three
assumpt.ions (see table 4.8). The frequencies of users in the
'stoppers' and 'continuers' group did not. vary greatly by
gender for either assumption (see t.able 4.91. The mean
number of concurrent medications was less for the 'stoppers'
across all assumptions. However, the confidence interval
overlapped between the two groups for the 30 and 60 day
assumptions. In addition, t.he number of doses t.aken per day
did not differ between the 'stoppers' and 'continuers' for
either assumption. The average cost. paid for antidepressants
did not. differ significantly between the 'stoppers' and
'continuers' for eit.her assumption. However, the mean cost
paid for other medicat.ions was greater in the 'continuers'
group for each of the three assumptions. This
complemented with non-overlapping confidence int.ervals
between the 'stoppers' and 'continuers' for each assumption.
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Table 4.8: Means and Confidence Intervals for ea.ch variable
by assumption and group (stopper or continuer) for SSRI
Users
Vari- One Prescription 30 Day 60 Day
able Assumption Assumption Assumption
(~, 950 (Mean, 950 (Mean, 950
Confidence Confidence Confidence
interval) Interval) Interval)
1 Pres. >1 PrClS <-3D >30 <-60 >-60
Days days Days days
Aqe 42.06 44.87 41.73 44.86 41.74 44.96(39:""85- (44.27- (39.26- {44.27- (39.75- (44.36-
44.26) 45.48) 44.19) 45.46) 43.72) 45.57)
Concur- 1.45 1.84 1. 58 1.83 1. 61 1.83
ent Med {~- (1:15- (l"":"2'8- (~- ("l"":35- (~-
1. 72) 1. 941 1.891 1.92) 1. 861 1.931
Avq $7.16 $7.19 $7.35 $7.17 $6.79 $7.23
Cost (s"6"":"47- ($"6"":"92- ($6":59- ($6:91- ($6.15- (~-
per 7.86) 7.461 8.11) 7.44) 7.43) 7.501
Anti.
Avq $3.13 $4.64 $3.31 $4.61 $3.28 $4.66
Cost iT54=- (4~ (s"2"":""66- IS'4':""47- (2~ (4--:5"1-
per 3.72) 4.791 3.95) 4.76) 3.79) 4. all
Other
Number 1. 27 1.28 1.28 1.28 1.25 1.29
per day (~- (1""':25- (l":"TI- (1"":25- {r:T5- (1:26-
1. 39) 1. 31) 1. 42) 1.311 1.35) 1.321
110
Table 4.9 Frequency and Percentage (wi thin each Assumption
by sex) of SSRI Users in Each Group by the Three Assumptions
and Subject Sex
Variable One
Prescription
Sex 1 >1
Pres. Pres
Female 83 982
(7.8) (92.2)
30 Day
Assumption
<-30 >30
Days Days
71 994
(6.1) (93.3)
60 Day
Msumption
<-60 >60
Days Days
101 964
(9.5) (90.5)
Mal. 40
(7.7)
411 35
(92.3) (6.8)
482 51
(93.2) (9.9)
466
190.1)
4.2.2.3.2 Tricyclic Grouo; The age pattern was
consistent across all three assumptions in that the mean age
for the 'continuers' group was greater than that for the
'stoppers' group. The confidence intervals for the groups
did not overlap suggesting that a real difference in the
means for the groups did exist (.5ee table 4.10). The
frequencies of users in the 'stoppers' and 'continuers'
group did not vary greatly by gender for either assumption
(see table 4.11). A similar pattern was evident in the mean
number of concurrent medications. The 'continuers' had a
higher mean number of concurrent medications than the
'stoppers' and this was also complemented by non-overlapping
confidence intervals. In addition. the number of doses taken
per day did not differ between the 'stoppers' and
III
Table 4.10: Means and Confidence Intervals for each variable
by assumption and group (stoppetr or continuer) for Tricyclic
~
Vari- One Prescription 30 Day 60 Oay
able Assumption Assumption Assumption
(~, 95% (~, 95% (~, 95%
Confidence Confidence Confidence
interval) Interval) Interval)
1 Pres. >1 Pres < 30 >30 <...60 >60
Days days Days days
Age 43.35 49.17 42.42 49.16 43.04 49.34
C41.39- (48.56- (40.37- (48.55- (41.2B- c48:"TI-
45.31) 49.78} 44.46) 49.77) 44.80) 49.96)
Concur- 1. 62 2.20 1. 55 2.19 1. 62 2.21
rent {139- (2":10- (~- (2""":10- {I"""":"40- ("2""":11-
Me<! 1.85) 2.29) 1.801 2.29) 1. 83} 2.311
Avg $4.09 $4.40 $4.20 $4.38 $4.11 $4.39
Cost ($3"':7l- (4~ csJ:78- (s4:25- ($~- ($'4':"'25-
per 4.41) 4.54) 4.611 4.52} 4.53) 4.531
Anti.
Avg $3.81 $4.94 $3.42 $4.96 $3.65 $4.98
Cost {$~- (S~- ($~- ($4":80- ($3":"'01- ($'4"":"83-
per 4.52) 5.09) 4.00) 5.111 4.27) 5.14)
Other
Number 2.18 2.21 2.30 2.20 2.13 2.22
per clay (~- ("2":"15- {2.02- (2:""13- iT:92 ("2""":l5-
2.42) 2.27) 2.57) 2.26) 3.34.) 2.28)
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Table 4.11 Frequency and Percentage (wi thin each Assumption
by sex) of Tricyclic Users in Each Group by the Three
Assumptions and Subject Gender)
Variable One
Prescription
Sex 1 >1
Pres. Pres
Female 130 1135
(10.3) (89.7)
30 Day
Assumption
<:::a::30 >30
Days Days
113 1152
(8.9) (91.11
60 Day
Assumption
<-60 >60
Days Days
153 1112
(12.1) (87.9)
Male 74 519 60 533 86 507
(12.5) (87.5) (l0.1) (89.9) (14.5) (85.5)
'continuers' for either assumption. In terms of the average
cost of other drugs, the 'stoppers' had a lower mean cost
per prescription than the 'continuers'. This was consistent
across the three assumptions and the confidence intervals
between the 'stoppers' and 'continuers' did not overlap. No
mean differences in the average cost paid for the tricyclic
was evident between the groups.
4.2.3 Time Till First Non-compliant gap
Life tables survival curves were used to look at the
time till the first non-compliant gap stratified by
different levels of the predictor variables. Overall and
pairwise comparisons of the strata of survival curves for
each variable were competed using the Wilcoxan Gehan
statistic. Survival curves as well as tables documenting
II)
each comparison and the associated alpha level are presented
below. In most cases, only the survival curves for the 15
day assumption are shown. The associated curve tor the 30
day assumption can be found in the Appendix 1. Survival
curves tor all non-significant comparisons are presented in
the Appendix 8.
Since multiple pairwise comparisons were often
performed for each variable. the a. level was lowered to
decrease the probability of type II error. This was
calculated by dividing the standard a level of 0.05 by the
number of pairwise comparisons performed. Table 4 12 shows
the modified a level for each predictor variable.
Table 4.12; Modified a-levels calculated from ratio of
standard a-.05 to number of possible comparisons
Variable
cla.ss
Oases per Day
Sex
Cost of Other
Drugs
Cost of
Anti'd
Aqe
Concurrent
Medications
Number of
levels of
Va.riable*
2
2
Number of
Possible
Comparisons
1
1
10
10
Modified a-
level
0.050
0.050
0.050
0.011
0.011
0.005
0.005
"Variable levels can be in Tables oj.8 and 4.10
1"
4.2.3.1 Tricyclics Versus SSRI's; A preliminary
survival analysis was stratified by class. fiqures 4 1 and
4.2 present the preliminary survival curves comparing
subjects on SSRI's to those on tricyclics on the basis of
time till first non-compliant episode. for both the 15 and
30 day non-compliance assumptions, the difference in
survival curves was not significant (W(lj=0.23, p:.8798 and
W(lj- 3.80, p=.051 respectively). However, examination of
t.he curves does show that, alt.hough both classes show a
drop-off in compliance early in treat.ment, the tricyclics
show a great.er drop in compliance at about 50 days into
treatment. This pattern changes when the SSR!' s have a lower
cumulative probability of survival than the tricyclics at
approximately the 200~!'; day of treatment by the 15 day
assumption and at the 300'°· day of treatment by the 30 day
assumption.
4 _2.3.2 Predictor va.riables
4.2.3.2.1 Tricyclic Users; Table 4.13 shows the overall
comparisons for each variable for the sample who were
tricyclic users. Only significant pairwise comparisons are
shown. A complete table showing all pairwise comparisons
be found in Appendix 9. Age differences existed between
strata in the sample of tricyclic users.
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Table 4.13: Pairwise and Overall Comparisons of time to non-
compliance for the Various Levels of the Predictor Variables
for the Tricyclic Class
Vari.a.b~e Coapari.son Wi.lcozan ror Wi~cozan ror
Type 15 day 30 Day
assumption assumption
OveraJ.1 (2 W(l)-o.003, w(1)zo.793,
pairs) ~.959 p.3?3
~ Overa1l. (10 W(4)-'15.72, W(4)-'13.48,
pUrs) p.003 p=.009
<20 and 21-35 e'airwise W(1'-l.l6, W(ll-9.8S,
p-.Z81 p"'.OOZ'"
<20 and 36-55 e'airwise Wlll-s .68, W{l)-8.18,
p-.017 p-.OO4'"
<20 and 51-65 e'airwise W(1)-S.34, W(ll-8.22,
p-.02l p-.OO4'"
<20 and >65 e'airwise well-l3.96, W(ll-lO.SS,
p-.OOO" p,,".OOl"
21-35 and >65 e'airwise W(1I"'9.18, W(l) -0.18,p-.OOZ'" p-.676
Concurrent OVera1l. (10 W(4)'"'26.03, W(4).o::15.24,
Drugs pairs) pa.OOO- p=.OO4-
COllIparisons;
0 and 3-4 e'airwise Wlll-8.87, W(1I-4.39,
p-.003" p-.036
0 ~d ,.,5 e'airloiise "(11-17.3Z, W(1I-7.7Z,
p-.Q()l)" p"".OO5
1 ~d ,.,5 e'airwise WIlI-ls.73, WIlI-IO.27,
p-.OOO" p'"".001'"
Number/Day OV~aJ.l (2 W(II-30.21, W(I)s17.79, p
pairs) pa.OOO· ~.OOO·
Avg cost of OVeraJ.l. (3 W(2)"4.00, W(2)-2.63,
Other Drugs pairs) p .... 135 p=.26B
Avg cost of Overall '3 W(Z)"2.69, W(ZI-!. 83,
anti'd e'airs) p-.26 p-.4.01
"'Sl.gn~f~cant at the mod~fl.ed alpha level (see table 4.12)
((8
E'igure 4.3 shows the survival curves for the 15 day
assumption stratified by age group. The '>65' group showed
the greatesc cumulative probability of survival cill the
first non-compliant gap. The curves actually descend in
order of age group suggesting that the younger age groups
had a greater probability of having a non-compliant episode
early in treatment. Only two pairs of curves were
significantly different by the 15 day assumption, the '<20'
and '>-65 and the '21-35' and '>-65' age groups. The '<20'
and the '>=65' day curves were also significantly different
by the 30 day assumptions (see Appendix a for survival
curves). In addition, che '<20' curve was significantly
different from the '21-35', the '36-55', and the '51-65' age
groups by the 30 day assumption.
In terms of the number of concurrent medications,
several pacCerns were evident in the survival curves. As
be seen in Figure 4.4, the survival curves tor the 15 day
assumption descended in order from '>=5' to '0' suggesting
that the those taking more concurrent medications had a
greater probability of surviving longer till a non-compliant
gap than did those taking less concurrent medications. This
same pattern was also evident in the curves for the 30 day
assumption (see Appendix 8). Several of the pairwise
comparisons were also significant. For the 15 day
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assumption, the survival curves for the 'a' and '3-4', '0'
and '>=5', and the '1' and '>=5' groups were significantly
different. Only the 'I' and '>-5' comparison was significant
by the 30 day assumption. The other two groups did approach
significance but were not. significant because of the
st.ringent alpha values utilized (see Appendix B).
E'igure 4.5 shows the survival curves stratified by
number of doses per day. As can be seen from the survival
curves, the survival times till a first non-compliant gap
were shorter for the group taking more then one tricyclic
dose per day. The difference in these curves is
statistically significant by both the 15 and 30 day
assumptions.
No trends or significant differences were noted in t.he
survival curves stratified by levels of both cost. variables
and sex {see Appendix 91. This was consistent for both the
15 and 30 day assumpt.ions.
4.2.3.2.2 SSRI Users; Table 4.14 shows the overall and
pairwise comparisons for each predictor variable for the
SSRI users.
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Table 4.14: Pairwise and OVerall Comparisons of time to non-
compliance for the Various Levels of the Predictor Variables
for the 55R.I Class
Variable
Concurrent
Drugs
Comparisons;
a and 2
a and 3-4
Number/Day
Avg cost of
Other Drugs
Avg cost of
antidepressant
$4.01-8.00 and
>$8.00
comparison
Type
OV~a..U. (2
p&1.rs)
Overall (10
pairs)
Overall (10
pairs)
E'air....ise
E'airwise
Overall (Z
loairs)
Overall (J
pairs)
OVara.J.l (3
Pairsl
E'airv1.se
Wileo:ltan for
15 day
&Ssumption
W(l)-=O.OS,
p-.B2
W(4)"'4.37,
p-.36
W(4)-18.l8,
pz.001"
W(ll-lO 11,
p-.OOZ"
W(1)-lZ 75,
p-.OOO"
W(ll-B.IO,
f 0-. 00"
W{Z)-O.40,
p"..B4
W(2)_6.80,
p.033
W{ll-S.OO,
p-O.OH"
Wileo:ltan for
30 Day
asSUJllPtion
W(112Q.31,
p=.se
W(4)-6.30,
p-.178
W(lj-1.84,
p-.17S
1'0'(1)-4.44,
p=.OJS
W(1)-6.47, P
c.Ol"
W(Z)-3.47,
pc.1B
W(2)-6.35,
p. 04.2
W{l)-S.S4,
p-.Ol9
"Significant at the modified alpha level (see Table 4.12)
No significant differences between survival curves were
noted for sex or age. Inspection of the survival curve in
Figure 4.6 (15 day assumption) shows that although the age
curves do not differ significantly, they do follow the same
trend as the tricyclics. More specifically, they descend by
age with the older age groups having a greater probability
of longer survival times till the first non-compliant gap.
This was the case for both the 15 and 30 day assumptions.
In terms of concurrent medications, significant
differences did exist between the survival curves for the
'0' and '2' and the '0' and '3-4' groups. These differences
were significant only for the 15 day assumption. Inspection
of the survival curves reveals that those with greater
number of concurrent medications had a greater probability
of survival or longer survival times that those wit.h less
concurrent medications (see figure 4 7). This t.rend mirrored
the results from the tricyclic analysis.
figure 4.8 shows the survival curves st.rat.ified by
number of doses per day. As can be seen, the probability of
becoming non-compliant sooner is greater for the group
taking more then one dose per day. The difference in these
curves is statistically significant by both the 15 and 30
day assumptions.
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The survival curves stratified by cost paid per
prescription for other drugs did not differ significantly. A
significant difference was found between the '>$8.00' and
the '$4.00-8.00' groups for the cost paid for
antidepressants for the 15 day assumption. This comparison
approached significance for the 30 day assumption. In
addition, the difference between the '<S4.00' and the
'>S8.00' curves also approached significance for both the 15
and 30 day assumptions. An inspection of the survival curves
in Figure 4.9 shows that the >S8.00' group had a greater
probability of having a non-compliant gap than those paying
less that $8.00 per prescription. The difference between
these curves was especially pronounced around the 200 day
mark suggesting that continued treatment at high cost to the
consumer may adversely effect compliance.
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5 DISCUSSION
The current study utilized an administrative
prescription drug database to examine patient fill-refill
behaviours as well as to determine potential predictors of
non-compliance to antidepressant medications
S.l The Problem of Non-compliance
Non-compliance was measured in several ways_
Calculation of the percentage of non-compliant days allowed
for the examination of patterns of till-refill in non-
compliant patients who are difficult to identify clinically
because they remain under the care of their physician as
evidenced by continuous refills of medication. However, they
are non-compliant to the extent that they fail to fill some
of their prescriptions and thus have treatment gaps in their
fill-refill records (Steiner et a1., 19BBJ.
tricyclic users were greater than 75 percent compliant by
the percentage of non-compliant days measure. This is
consistent with results from other studies that. also
utilized a similar measure. Steiner et al. (1993) also used
this measure to determine the extent at non-compliance to
antihypertensive medications. They found that 75~ of the
sample reached 80 percent compliance. Kelloway et al.
1)1
(l994) state that the percentage of non-compliant days
measure may overestimate compliance because it assumes that
gaps in treatment are due to non-compliance. They suggest
that other events such as lost medications, sharing
medication with family members, or simply not taking the
medication at all will lead to an overestimation of
compliance.
As discussed above, a large percentage of users
greater than 75% compliant . .lUthough this result is
consistent with other studies that have used the same
measure, Gerbino (1993) suggests 75% compliance is not qood
enough for antidepressant medications. He suggests that for
depression, 90% of patients who take 90 percent of their
prescribed doses improve. In contrast, patients who take
less than 80 percent of doses will probably not improve. In
this study, 72.8% of the SSRI users and 70.1'0; of the
tricyclic users had less than 10 percent of days without
medications or were greater than or equal to 90 percent
compliant to their medication by this definition of
compliance. Thus, 27.2! of SSRI and 29.9% of tricyclic
had more than 10% of days without medication. According to
Gerbino (1993), this is the group who will not get
therapeutic value from the antidepressant (assuming that it
is prescribed for depression) .
Il2
The percentage of non-compliant days measure ignores an
entire sub-population of users who prematurely discontinue
therapy. The second outcome measure compared early
medication stoppers to medication continuers. In the current
study, the early medication stoppers were not a large group.
The first definition of medication 5topper, which defined
medication stoppers as those people who filled only one
prescription, classified only 9.5% of users as medication
stoppers. The second and third definitions, which defined
stoppers as those who were on the antidepressant for only 30
or 60 days respectively, classified 8.1% and 11.4~ of users
as medication stoppers. Other studies looking at
antidepressant medications have suggested that early
medication stoppers actually account for a much larger
portion of the entire population of users. Simon et al.
(1993) found that 35i! of depressed patients in a primary
care setting discontinued treatment after 30 days. Maddox et
a1. {l994J found that 32!" of depressed patients had stopped
antidepressant medication at 6 weeks into therapy. The
results from this study may show a smaller number of early
treatment stoppers for several reasons. First, the
population of clients using the Blue Cross program tends to
be primarily middle class individuals. Characteristics of
this sample such as higher education levels, employment
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status, or social economic status may affect continuation
rates. Second, other studies looking at discontinuation have
primarily used patients who are using the antidepressant for
the indication of depression. No such information was
available in the current study. Thus, it is possible that
discontinuation rates are different for the antidepressants
as a whole than they are for those prescribed only for
depression.
The survival curves did give some indication of the
time course of non-compliant behaviours in the population
of antidepressant users. The initial curves for each class
show that the greatest probability of having a first non-
compliant episode occurs early in therapy for both classes
at approximately 40 to 50 days. The survival curves depict a
fairly unifortn decline in the cumulacive probability of
survival lof not-having a non-compliant episodel over the
remainder of therapy. Examination of these survival curves
provided information on exactly when during therapy
compliance problems may ::>ccur. These results may be helpful
in determining when during the course therapy, interventions
which aim to increase compliance would be most effective.
""
5.2 Medication Class and Compliance
Although t.he comparisons of the SSRI's and t.ricyclics
did not show significantly different patterns of compliance
between the two, several interesting patterns were noted.
First, the tricyclics did have a slightly greater
discontinuation rate by each of the three assumptions of
'early stopper'. This is consistent with information from
clinical trials and other population studies t.hat suqgest
that the tricyclics are not as well tolerated as the SSRI's,
especially early in therapy, because of a worse side effect
profile (Simon et al , 1993; Anderson et al., 1995).
A comparison of the survival curves directly comparing
the classes was not significant but several patterns did
exist. More specifically, the tricyclics shewed a greater
drop than the SSRI's at the 50 day mark. In contrast, the
SSRI's showed a greater decrease in the cumulative
probability of survival between the 200-300 day marks. This
decline was consistent across the remainder of the time
course of therapy. These differences may actually be related
to the differing side effect profiles of the two classes.
The tricyclics tend to have more troublesome side effects
such as constipation, blurred vision, and urinary retention
which might result in early discontinuations or reductions
in compliance (Lin et al., 19931. The SSRI's showed a
'"
greater drop in compliance than the tricyclics later in
treatment. This may possibly be related to the fact that the
SSRI's tend to cause sexual dysfunction in approximately one
third of users (Bernstein, 1995). This side effect may be
tolerated when the illness is being treated but once a
person goes into maintenance and is generally asymptomatic,
this side effect may be more troublesome and possibly result
in decreased compliance later in therapy.
5.3 Predictors of Non-compliance
Several of the variables were consistently associated
with each compliance measure. In particular, age, the number
of concurrent medications, and the number of doses per day
all varied as a function of compliance. Patient cost and sex
were not consistently associated with compliance.
5.3 1 Aqe
Subject age showed specific trends in terms of
compliance. More specifically, as age dec~eased, non-
compliance increased. Although this trend was evident in the
descriptive statistics (means and frequencies), more
stringent statistical tests of significance showed that this
association was weak with the greatest difference existing
between the youngest and oldest age groups. The age
association was stronger for the tricyclic class than the
SSRI class.
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?revious literature has been conflicting in terms of
age (see section 2.4.2.2). A very limited number of studies
have looked specifically at the antidepressants. Last and
Thase 119851 and Lin et a1. 119951 both found that age was
not associated with early termination from pharmacologic
treatments in depressed patients. Many population database
studies that have looked at age in relation to other
medications including antihypertensive, lipid-lowering, and
anticonvulsant medications have found no or weak
associations with age (Monane et al., 1994; Larret et al.,
1990; Stanaway et al., 1985). Although the results from the
current study, like several previous studies, do suggest an
age related trend in compliance the association is very
weak. Lorenc and Branthwaite (1993) suggest that the age
related association to non-compliance may actually be the
result of separate factors which might correlate .... ith age
which are actually related to compliance. For example,
accurate knowledge of the regimen, belief in the importance
of taking tablets exactly as prescribed, low resentment of
time spent waiting to see doctor, less fear of illness, and
living with a relative may all correlate with age and
actually be predictors of compliance.
IJ7
5.3.2 Regimen Complexity
The complexity of the medication regimen as indicated
by the number of concurrent medications and the number of
doses per day did show specific patterns in terms of patient
compliance.
Compliance increased as the number of concurrent
medications increased. This result was consistent
outcome measures and drug classes. The medication stoppers
had a lower mean number of concurrent medications t:.han those
who continued an the antidepre~sant. The mean percentage of
non-compliant days also decreased as t:.he number of
concurrent medications increased. Although these patterns
were quite evident in the data, more stringent statistical
tests (i. e. confidence intervals, regression analysis)
showed that the differences between levels were not large
with only a weak association between the number of
concurrent:. medications and compliance.
Current opinion regarding the effect of the number of
concurrent medications on compliance is that compliance
decreases as the number of concurrent medications increase.
This pattern is thought to be due to the increase in
complexity of the medication regimen. The current study,
well as similar studies in population settings by Hamilton
et al. (1992) and Monane et al. (1994) suggest that the
IJB
opposite trend may exist. Hamilton et al. (1992) found that
compliance to a wide range of drug therapies improved as the
number of concurrent medications increased. Monane et al.
found that the percentage of non-compliant days to cardiac
therapy decreased as the number of concurrent medications
increased. Hamilton et al. (1992) suggest several possible
explanations. First, because of the complexity of the
regimen, subjects may be forced to develop dosage
administration schedules that ensure compliance. Second,
people with more medications may be perceived as haVing a
greater risk of non-compliance because of the compiex
regimen and thus, may receive more medication counseling.
Although this research does not absolutely confirm that past
studies are wrong, it does reiterate the need for further
research in this area, predominantly in settings where
compliance is not influenced by the researcher. One problem
with this measure, which is also true of most of the
predictors used, is that it may be related to another
variables. For example, the number of concurrent medications
often increase as age increases and thus it is difficult to
ascertain what factor is actually influencing compliance.
The second measure of medication complexity, the number
of doses per day, also showed distinct trends in terms of
compliance. The mean percentage of non-compliant days was
"9
greater in the group taking more than one dose per day. This
was consistent for both the tricyclic and SSRI classes.
However, regression analysis suggested that the percentage
of the variance accounted for by this measure was not great.
In addition, the early medication stoppers did not differ
from the medication continuers in the mean number of doses
per day. This may indicate that the number of doses per day
may be a barrier to compliance for those people who continue
on with the medication. In addition, survival analysis
showed that individuals taking more than one administration
per day were significantly more likely to have a non-
compliant gap earlier in therapy than those taking one
administration per day. Again, these findings were
significant for both classes.
As discussed in section 2.4 1.2, most of the literature
suggests that the number of doses per day increases the
complexity of the medication regimen and thus lead to a
decrease in patient compliance. This study is generally
consistent with these findings.
This measure does have a number of inherent problems.
First, the number of doses per day was calculated from the
number of medication dispensed and the number of days
supply. Problems with data contamination in the 'Days
Supply' field in the database may have resulted in incorrect
1-10
calculations for the number of doses per day. In addition,
it was inferred that, because a person was taking more than
one pill per day, that each unit of medication was taken
separat.ely. According to Hamilton et ai. (1992) this is a
generally reasonable assumption for drugs t.hat. come in a
wide variety at tablet strengths as do most of the
antidepressants. However, it should be reiterated that this
was an indirect measure of the nwnber of doses per day.
5.3.3 Patient Cost
Neither average patient cost for the antidepressants
average patient cost for other drugs appeared to be
consistently associated with compliance for either class.
One noticeable trend did exist for the average patient cost
of the SSRI in both the percentage of non-compliant days and
the survival analysis. More particularly, there was a
significant difference in the mean percentage of non-
compliant days between the group paying S8.01 or more per
SSRI prescription and t.hose paying S4. 00 or less per SSRI
prescript.ion. In addition, those paying S8.00 or more per
prescript.ion had a greater probabilit.y of having a non-
compliant gap earlier in therapy than those paying an
average of $4 00 or less per prescript.ion.
Previous studies have suggested that increased cost to
the patient negatively impacts on compliance (Thompson et.
'"
al., 1995; Beardon et al., 1993). The current study suggests
that the average cost that an individual pays for the other
medication that slhe takes does not effect compliance to the
antidepressant medication. However, the direct cost that a
patient is paying for the antidepressant medication itself
may effect compliance to the antidepressant especially if
that cost exceeds a certain level (in this study >$8.00).
Although several other outcome measures did not indicate any
association with cost, this significant association does
indicate that further research should attempt to ascertain
whether greater magnitudes of cost impact on compliance. In
the current study, the function of studying the
antidepressant and other costs separately was t.o ascertain
which cost components (direct cost of antidepressant. or
costs associated with other drugs) influenced non-compliance
to the antidepressants. Future research should probably look
at impact of the total cost of all treatments upon non-
compliance. In addition, future research should look at
overall costs to a family. For example, a measure of total
costs could have looked at the total cost per family and
whether or not high family costs impact on fill-refill
compliance.
A problem that existed with the measurement of the
average cost per prescription in this database involved the
,n
fact that prescriptions were not filled for uniform time
periods. Thus, cost was dependent on prescription duration.
One person may have paid more tor the same drug than another
person because they had the prescription filled for a longer
duration not because they were actually paying more for the
drug itself. The cost measure is valid in as much as it
allows us to ascertain whether the cost to an individual at
one point in time (i. e _ when they pick up their
prescription) affects compliance. However, the lack of
significant outcomes in this measure may, in part, be due to
the fact that the average price paid for a prescription was
dependent on duration.
5.4 Evaluation of the Blue Cross Database
Examination of the Blue Cross administrative database
revealed a number of problems. Contamination of the data,
missing data values, as well as inherent limitations in the
database itself resulted in problems that may have affected
the results.
Errors in data entry presented problems for the
analysis of compliance. Default values in the 'Days Supply'
field and errors in date of birth entries were only two
instances where problems existed. In these cases, strict
protocols were initiated to clean the data. It is possible
that contaminated information m.ight have existed in other
fields as well.
A number of problems were identified which were beyond
the central of the researchers. For example, a small
percentage of the male subjects 13.Sill were identified who
had prescriptions for a birth control pill of some kind.
Investigation of this phenomenon with Blue Cross revealed
that, a women's birth control prescription could have
accidentally been entered into her husband's file if he had
filled the prescription. This was not a standard practice by
the pharmacy but a result of accidental data entry. It is
unknown to what extent this problem existed in the data.
Another problem that was encountered was a result of a
confidentiali ty measure taken by Blue Cross. Because
could not be issued, the data was presented to the
researchers with only family 1D numbers. This necessitated
the correction of files to add individual identifiers.
Although a strict protocol was followed in the adding of the
individual identifiers, not enough information was available
to ensure that individuals were always identified correctly.
For example, in the case of twins, because the family 1D
number, the date of birth, and the sex would all be the
same, the records of both twins would be combined as one
person.
,..
In general, although a number of problems were
identified through careful inspection of the data, it is
possible that other problems may have existed that were not
addressed through any data cleaning process such as the
problem of a prescription fill being placed in the wrong
person'S file (Le. a husbands or wives file). The problems
encountered in this study, as well as potentially
unidentified problems, should be seriously considered in
future studies that use this and similar databases as a
source of information.
An inherent characteristic of the Blue Cross Database
that was problematic was the lack of documentation regarding
drop-outs or starters to the Blue Cross Program. An
individual may have been misclassified as an 'early
medication stopper' when, in fact, they had switched to
another insurance plan. Also, the first medication reported
in the Blue Cross Database may not have been the first
antidepressant in that course of therapy for an individual
who had recently switched into the Blue Cross Program.
Also, if a person had two sets of coverage under the
Blue Cross program, that person would be considered two
different people in the Blue Cross records. For example, if
a women had coverage under her husband's family plan but
also had individual coverage through an employer, then she
'"
would have had two separate sets of records in the database.
This problem could have led to one person being counted as
two separate people in the analysis.
Private administrative insurance claims databases
designed to allow insurance companies to monitor their
spending and costs incurred for each client and their
dependents. Although they contain specific details, the
information may be contaminated or incorrect. Compliance
research such as that carried out in the current stUdy
requires very specific information concerning the exact
dates and quantities of medication dispensed. On the
surface, the Blue Cross Database provided some of this
information. However, close inspection of the data revealed
that it contained many data entry errors. An indication of
the magnitude of this problem is the 21.8:!; of the original
6389 subjects who were eliminated from the study because of
contaminated (eg default values such as '999' or' 0' J
missing records in the "Days Supply" field.
5.5 Problems Associated with Usinq Databases to Study
Compliance
The use of population databases have many advantages in
the study of compliance. They allow the researcher access to
a wide body of data for a specific population. They are
often less expensive than studies where large amounts of
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data have to be collected through surveys or clinical
trials. In addition, patient behaviours are not influenced
by the intervention of the researcher. However, the Blue
Cross database as well as any other administrative databases
of its kind have inherent liInitations tor compliance
research.
First, no information is available on indications tor
use of the medication. This is particularly problematic for
the antidepressants because of the wide range of indications
they can be prescribed for. This wide range of indications
is associated with varying treatment characteristics such as
optimal doses or duration of treatment. Thus, in the current
study, an assumption was made that individuals starting new
courses of therapy would be taking the medication for an
extended duration as would be the case for an individual
prescribed an antidepressant for depression; the most common
indication that the antidepressants are used for lMcCombs et
a1., 1990; Wagner et a1., 1992, Simon et a1., 19931.
However, individuals using the medication for other
indications may have been using it tor a shorter duration of
time. Thus, they may have been wrongly classified as 'early
medication stoppers' .
Another problem related to the study of antidepressants
in a database is the varying time course of the dosing of
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medication. A person may be on a full dose of an the
antidepressant while slhe is in a depressive episode.
However, if the person remains on the medication for
prophylactic reasons (referred to as a maintenance period),
the dose may be tapered. In some cases the physician may not
change the prescription. Sihe may only tell the patient to
take half the dose (eg. one pill per day instead of two).
This change would not be reflected in the pharmacy's records
and thus would result in apparent gaps in treatment.
The problem of incorrect classification of non-
compliance is a issue as well. Because most drug plan
databases do not perceive a need to gather information on
reasons for discontinuations or gaps in therapy, no
information is documented on why gaps in treatment In
this study, it was assumed that non-compliance was the
reason for gaps in treatment less than 90 days in length. In
fact, this may not have been the reason for the gaps. For
example, subjects may have been hospitalized and thus had
their medications provided by the hospital, they may have
received medication from other sources such as another
insurance plan or a family member, or the health care
provider may have stopped or interrupted the therapy. A more
comprehensive database with links to hospital records,
physician records, or other sources of prescription
'"
medication would allow for a greater deal of certainty in
the assumption of non-compliance.
In addition, drug plan databases do not provide
information on other non-pharmaceutical therapies that a
person might be using. This is particularly important for
the study of compliance to therapies for disorders like
depression where a person might be using other therapies to
complement the antidepressant therapy such as psychotherapy.
Finally, the study of refill compliance measures from
databases looks only at the subset of the population who
actually fill their first prescription. Those who do not
fill a first prescription are lost to database researchers.
5.6 Recommendations for Database Improvement
Several improvements or additions to the Blue Cross
database would increase the usefulness of the data for
compliance research. The use of common patient identifiers
(e.g. MCP Numbers) would allow for increased linkages with
other databases from hospitals, clinics, or other coverage
plans that would provide necessary information on
indication, hospital admission times, and number of doses
per day.
In addition, because data entry was such a large
problem in terms of data reliability, educating pharmacists,
pharmacy techr1icians, or data entry staff in the importance
I"'
of accurate data entry is essential. Some form of marker to
indicate that a subject has just joined the Blue Cross
program or to signify that they have dropped out of the
program would also prove useful. Linkages of records
belonging to an individual who has separate policies is also
an essential improvement.
Many researchers and agencies such as governments
interested in studying or monitoring drug utilization,
patient compliance, post marketing surveillance of new
drugs, drug interactions, benefit and risks of medications,
and drug use information (West, 1993). Improvement of
administrative databases as described above would have great
value in these research initiatives.
It would be in the best interests of private agencies
such as Blue Cross to set up data sources that not only
monitor expenditures, but which also allow for research
opportunities. For example, research in cost-benefit and
over utilization could result in more effective use of
medications and thus potentially lead to cost savings for
private insurance plans. In terms of compliance, it is in
the best interests of insurance companies to facilitate
research in this area because of the proven effect of
compliance on patient outcomes (see section 2.1.3).
Increased information on compliance could lead to improved
.so
interventions to improve patient compliance. Improved
compliance by subscribers may reduce the costs incurred by
insurance agencies because of the ramifications of non-
compliance.
Increased linkages through the use of conunon patient
identifiers and agreements between governments and private
agencies would avoid duplication of information and would
maximize the potential for high caliber research
particularly in the area of compliance. A major condition of
such unions between various agencies would be universal
standards which would ensure reliability of the data
5.7 Future Compliance Research Recommendations
future research on antidepressant compliance needs to
utilize data sources that are very comprehensive and which
contain accurate and reliable information on such things as
indication. The Saskatchewan population database \oIhich links
records via conunon patient identifiers between various
segments of the health sector (Le. hospitals etc. J would be
an example of a comprehensive of data. Use of
comprehensive data sources where all information on any
partiCUlar client is readily linked through common
identifiers would allow researchers to access all pertinent
information such as indications for use. For example,
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prescription refill records would be available via insurance
companies such as Blue Cross and information on indication
would be available through computerized files in clinics.
These records would optimally be linked via a common
identification number.
It would be interesting to compare compliance among
those taking the medication for different indications.
Another group that may prove interesting to study are the
group of people .....ho switch between classes of
antidepressants (this group was eliminated from the current
study). It would be interesting to look at compliance in a
population that engages in medication switching in order to
view the possible effects of this factor on compliance. In
terms of predictors of compliance, further research should
explore cost and regimen complexity as predictors. Although
regimen complexity has been studied widely for other
medications. research on antidepressants is lacking in this
area. This is probably due to the fact that most
antidepressant regimens involve once or twice daily dosing.
More specific research could help in tailoring prescribing
gUidelines in order to maximize both compliance and
therapeutic benefit. The age and sex variables have been
Widely studied with no consistent patterns found across
studies. The idea put forward by Lorenc et al. (1993) that
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age might actually appear to be related to other variables
which effect compliance should be studied further. This
suggestion also reiterates the problems associated with
determining predictors of compliance behaviours. All
behaviours are very complex and it is highly probable that a
combination of many highly complex factors impact upon an
individuals decision to comply to a prescribed regimen.
Thus, as was evident in the regression analysis, individual
predictors will probably only account for a small portion of
the variance in compliance behaviours. Research should
probably focus on developing more complex models of
compliance which consider multiple factors such as
individual patient characteristics (e.g., behaviours,
attitudes) as well as external factors such as patient-
health care provider interactions, family and social
influences, as well as specific disease states le.g.
severity of depressionl. Only when this is done can
effective interventions aimed at improving compliance be
developed.
'53
References
Anderson, I.M. and Thomenson, B.M. (1995). Treatment
discontinuation with selective serotonin reuptake inhibitors
compared with tricyclic antidepressants: a meta-analysis.
BMJ. 310; 1433-8.
Andrade, S.E., Walker, A.M.,. Gottlieb, L.K., Hollenberg,
N.K., Testa, M.A., Saperia, G.M, Platt, R. (1995).
Discontinuation of antihyperlipidemic drugs - Do rates
reported in clinical trials reflect rates in primary care
settings. The New England Journal of Medicine. 332(17);
1125-29.
Arana, G.W. and Hyman, S.E. (1987). Handbook of Psychiatric
Drug Therapy U.S.A.:
Baird, M.G., Bentley-Taylor, M.M., Carruthers, S .G., Dawson,
K.G., Laplante, L.E., Larochelle, P., MacCannell. K.L.,
Marquez-julio, A., Silverberg, L.R., and Talbot, P. (1984}. A
study of efficacy, tolerance, and compliance of once-daily
versus tWice-daily metoprolol (Betaloc) in hypertension.
Clinical and Investigative Medicine. 7(2); 95-102.
Beardon, P.H.G., MCGilchrist, M.M., McKendrick, A.D.,
McDevitt, D.G., MacDonald, T.M. 119931. Primary non-
compliance with prescribed medications in primary care. BMJ.
307(2); 846-8.
Berkow, R., Flethcher, A.J. {edsl (19921. The Merck: Manual
(16~!\ ed). 1604-5.
Bernstein, J.G. (1995). Handbook of Drug Therapy in
Psychiatry. Toronto: Mosby. 113-63.
Bond, C.A. and Monson, R. (1984). Sustained improvement in
drug documentation, compliance, and disease control.
Archives of Internal Medicine. 144, 1159-62.
Bradford, R.H., Shear, C.L., Chremos, A.N. et.al. (1991)
Expanded clinical evaluation of lovestatin study results I.
Efficacy in modifying plasma lipo-proteins and adverse event
profile in 8245 patients with moderate hypercholesteromia.
Archives of Internal Medicine. 151; 43-9.
Brody, T.M., Larner, J., Minneman, R.P., Neu, H.C. (1994}.
Human Pharmacology: Molecular to Clinical. Toronto: Mosby,
p.333 42.
",.
Canner, P.L. and Forman, s.A. (1980). Influence of compliance
to treatment. and response of cholesterol on mortality in
the coronary drug project (The Coronary Drug Project Research
Group). The New England Journal of Medicine 303(181, 1038-41.
Christensen, D.B. (1978). Drug-taking compliance: A Review
and Synthesis. Health Services Research, 170-87.
Col, N., Fanale, J.E., and Kronhom, P. (1990). The role of
medications non-compliance and adverse drug reactions in
hospitaliz.ations of the elderly. Archives of Internal
Medicine, 150, 841-45.
Cramer, J.A. and Spilker, B. (1991). Patient Compliance in
Medical Practice and Clinical Trials. New York: Raven Press.
Eisen, E.A., Miller, O.K., Woodward, R.S. (1990) The effect.
of prescribed daily dose frequency on patient medication
compliance. Archives of Internal Medicine. 150; 1881-4.
Fletcher, s.W., pappius, E.M. (1979). Measurement of
medication compliance in a clinical setting. Archives of
Internal Medicine. 139; 635-38.
Forsyth, D.R. (1990). Group Dynamics. California: Wadsworth,
Inc.; 29-30.
frank, E., Perel, J.M., Mallinger, A.G., Thase, M.E., Kupfer,
D.J., (1992). Relationship of Pharmaclogic compliance to long
term prophylaxis in recurrent depression. Psychopharmacology
Bulletin. 2813', 231-35
Gallagher, E.J., Viscoli, C.M., Horwitz, R.t. (1993). The
relationship of treatment compliance to the risk of death
after myocardial infarction in women. JAMA, 270 (6), 142-44
Gerbino, P.P. (1993). Patient Compliance. The Annuals of
Pharmacotherapy. 21, 53-519.
Goodman, W.K., McDougle, C.J., Price, L.H. (1992).
2harroacotherapy of obsessive compulsive disorder. Journal of
Clinical Psychiatry. 53 (4); 29-37.
Gordis, L. conceptual and Methodologic Problems in Measuring
2atient Compliance. In Haynes, R.B., Taylor, D.W., Sackett,
D.L. (1979). Compliance in Health Care. Baltimore: John
Hopkins University Press. 23 45.
ISS
Gordis, L., Markowitz, M., Lilenfeld, A.M. (1969). The
Inaccuracy in using interviews to estimate patient
reliability in taking medications at home. Medical Care;
7;49-54.
Gurwitz, J.H., Glynn, R.J., Monane, M., Everitt, D.E.,
Gilden, D., Smith, N., Avorn, J. f19931. Treatment for
glaucoma: compliance by the elderly. American Journal of
Public Health. 83(5); 711-16.
Hamilton, R.A., Briceland, L. L., (1992). Use of prescription
refill records to assess compliance. American Journal of
Hospital Pharmacy 49: 1691-6.
Harris, W.A., Kurdyak, P.A. eds(1997). MCCQE; Review Notes
and Lecture Series. Psychiatry 41-3.
Haynes, 8.R. (1979). Determinants of Compliance: The Disease
and the Mechanics of Treatment. In Haynes,B.R., Taylor, D.W.,
Sackett, D.L. (1979). Compliance in Health Care.London: The
John Hopkins Press. P. 51 54
Hulka, 8.5. (1979). Patient-Clinician interactions and
compliance. In Haynes,a.R., Taylor, D.W., Sackett, D.L.
(1979). Compliance in Health Care. London: The John Hopkins
Press. P. 63-77.
Jones, J.K., Gorkin, L., Lian,J.F., Staffa, J.A., Fletcher,
A.P. (1995). Discontinuation of and changes in treatment
after start of new courses of antihypertensive drugs: a study
ot a United Kingdom population. eMJ. 311, 293-5.
Kasper, S. (19941. Comparative efficacy of antidepressants.
Drugs. 43 (Suppl. 2); 13-23.
Katon, W., VonKorff, M., Lin, E., Bush, T., Ormel, J. 119921.
Adequacy and duration of antidepressant treatment in primary
care. Medical Care. 30(1), 67-6.
Katzelnick, D.J., Kobak, K.A., Jefferson, J.W., Greist, J.H.,
Henk, H.J. (1996). Prescribing patterns of antidepressant
medications for depression in a HMO. Formulary. 31; 374-387.
Ke1loway, J.S., Wyatt, R.A., Adlis, S.A. (1994). Comparison
at patients compliance with prescribed oral and inhaled
asthma medications. Archives of Internal Medicine. 154; 1349-
54
IS.
Ketai r R. (1976). Family Practitioners knowledge and
treatment of depressive illness. JAMAr 235, 2600-03
Klerman, G.t. 11992}. Treatments for panic disorder. Journal
of Clinical Psychiatry. 53 {31; 15-19. ---
Krogh, C.M.E. (ed.), (19941. Compendium of Pharmaceuticals
and Specialities. Ottawa: Canadian Pharmaceutical
Association.
Lacour r A. and Lelorier, J. (1995). Measuring compliance to
chronic drug therapies with databases: Comparison between two
groups of hypolipidemic drugs. Montreal: unpublished
abstract.
Larrat r E.P., Taubman, A.H., Willey, C. (l990). compliance-
related problems in the ambulatory popUlation. American
Pharmacy NS30 {2}; 18-23.
Last, C.G., Thase, M.E .. Hersen, M., Bel lack, A.S.,
Himmelhoch, J.M. (1985). Patterns of attrition for
psychosocial and pharrt1Ucologic treatments of depression.
Journal of Clinical psychiatry. 46: 361-66.
Lin r E.B., Von Korff, M., Katon, W." Bush, T., Simon, G.E
Walker, E., Robinson, P. (1995). The role of primary care
physician in patient's compliance to antidepressant therapy.
Medical Care, 3311J, 67-74.
Lorenc, L., and Branthwaite, A. (l993), Are older adults less
compliant with prescribed medication than you.'1.ger adults'?
British Journal of Clinical Psychology. 32, 485-92.
Maddox, J.C., Levi, M., and Thompson, C. (19941. The
compliance with antidepressants in general practice. Journal
of Psychopharmacology. a{l); 43-53.
Maronde, R.F., Chan, L.S., Larsen, F.J., Strandberg, L.R.,
Laventurier, M.F., Sullivan, S.R. {l989}. Underutilization
of antihypertensive drugs and associated hospitalization.
Medical Care, 27 (l2), 1159-66.
McCombs J.S., Nichol, M.B., Newman, C.M., Sclar, D.A. (1994).
The costs of interrupting antihypertensive drug therapy in a
medicaid population. Medical Care, 32 (3), 214-26.
McCombs, J.S., Nichol, M.B., Stimmel, G.L., Sclar, D.A.,
157
Beasley, C.M., Gross, K.W. (1990). The cost of antidepressant
drug failure: a study of antidepressant use patterns in a
Medicaid population. Journal of Clinical Psychiatry. 51 (61,
60-9.
Michenbaum, D. and Turk, D.C. (1987). Facilitating Treattnent
Compliance: A. Pract.it.ioner's Guidebook. New York: Plenum
Press.
Monane, M, Bohn, R.L., Gurwit.z, J.M., Glynn, R.J., Avorn, J.
(1994). Noncompliance with congestive heart failure therapy
in the elderly. Archives Internal Medicine. 154; 433-37.
Montgomery, S.A., Henry, J., McDonald, G., Dinan, T., Lader,
M., Hindmarch, I., Clare, A., Nutt., D. (1994). Select.ive
serotonin reuptake inhibitors: meta-analysis of
discontinuation rates. Internat.ional Clinical
Psychopharmacology. 9, 47-53.
Montgomery, S.A., Kasper, S. (1995). Comparison of compliance
between serotonin reuptake inhibitors and tricyclic
antidepressants: a meta-analysis. International Clinical
Psychopharmacology. 9 (Suppl 4 j, 33-40.
Myers, E.D., Branthwaite, A. (1992). Out.-patient compliance
with antidepressant medication. British Journal of psychiatry
160, 83-6.
Myers, E.D., Calvert, E.J. (1984). Information, compliance
and side effects: A study of patients on antidepressant
medication. British Journal of Clinical Pharmacology. 17, 21-
5.
O'Connor, Allen, V., Hilbert, R., Stanaszek, W. (1981). Some
fact.ors influencing prescription filling. On Continuing
Practice. 8 (1), 3-7.
Park, L.C., Lipman, R.S. (1964). A comparison of pat.ient
dosage deviation reports wit.h pill counts.
Psychopharmacologia. 1964; 6, 299-302.
Paykel, E.S. (1995). Psychotherapy, medication combinations,
and compliance. Journal of Clinical Psychiatry. 56(suppl 1);
24-30.
Practice Guideline for Major Depressive Disorder in Jl..dults -
American Psychiat.ric Association. (1993). American Journal of
Psychiatry; 150 (4), Supplement.
158
Psaty, 8.M., Koepsell, T.D., Wagner, E.H., LoGerfo, J.P.,
Inui, T.S. (1990). The relative risk of incident coronary
heart disease associated with recently stopping the use of ~­
Blockers. JAMA, 263 (12), 1653-57.
Puller, T., Birtwell, A.J., Wiles, P.G. (1988). Use of a
pharmacologic indicator to compare compliance with tablets
prescribed to be taken once, twice, or three times daily.
Clinical Pharmacology Therapy. 44; 540-5.
Rogers, P.G. and Bullman, W.R. (1995). Prescription Medicine
Compliance: A Review of t:he Baseline of Knowledge - A Report:
of the National Council on Patient Informat:ion and Education.
Journal of Pharmacoepidemiology. 3 (21, 3-36.
Roth, H.P. and Berger, D.P. (1970) Studies of patient:
cooperation in ulcer treacment. In Christensen, O.B. (1978)
Drug-taking compliance: a review and synthesis. Health
Services Research. 78; 171-87. --
Rovell!, M., Palmeri, D., Vossler, E., Bartus, s., Hull, D.,
Schweizer, R. (1989) Noncompliance in organ transplant
recipients. Transplant Proc, 21: 833-834.
Shaw, E., .lulderson, J.G., Maloney, M., Jay, S.J., fagan, D.
(1995). Factors associated with non-compliance of patient:s
taking antihypertensive medications. Hospital Pharmacy. 30 (3) ;
201-07.
Simon, L.A., Levis, G., Simons, J. (1996). Apparent
discontinuation ratoes in pati<:nts p~esc~ibed lipid-lc'.·te=i.=-:.;
drugs. Medical Journal of Australia. 164 (19); 21J13-11.
Simon, G.E., VonKorff, M., Wagner, E.H., Barlow, w. (1993).
Patterns of antidepressant use in community practice. General
Hospital PsYchiatry. 15, 399-408. ---
Sneddon, P.L., Farrall, D.L. (1989). Medication compliance in
elderly patients. The Pharmaceutical Journal, Aug 5, R18-20.
Stanaway, L., Lambie, D.G., Johnson, R.H. (1985). Non-
compliance with anticonvulsant therapy as a cause of
seizures. New Zealand Medical Journal. 98, 150-2.
Steiner, J.F., Koepsell, T.D., Fihn, S.D., Inui, T.S. (1988).
A general method of compliance assessment using centralized
,,,
pharmacy records. Medical Care. 26(8}; 814-22.
Steiner, J.F., Prochazka, A.V. (1991). The assessment of
refill compliance using pharmacy records: methods validi tv,
and applications. Journal of Clinical Epidemiology 50 (1); .
105-16.
Steiner, J.F., Robbins, L.J., Roth, S.C., Hammond, W.S.
(1993). The effect of prescription size on acquisition of
maintenance medications. Journal of General Internal
Medicine. 8; 306-10. ----
Thomson, A.B.R., Shaffer, E.A. eds (1994). First Principles
of Gastroenterology, 2"-:! ed. 149,317.
Thompson, L.G. and McMillan, J.S. (1995). Compliance to
cholesterol-lowering drugs in general practice. Unpublished
manuscript from Health Services Utilization and Research
Commission, Saskatoon.
Thompson, J., Rankin, H., Aschcroft, C.W. (1982). The
treatment of depression in general practice. Medical Care.
30(li; 67-76.
Tyrer, P. (1988). Prescribing psychotropic drugs in general
practice. British Medical Journal. 296, 588.
Wandless, I, Mucklow, J.C., Smith, A, Prudham, D. (1979).
Compliance with prescribed medicine: a study of elderly
patients in the community. Journal of the Royal College of
General Practitioners. 29; 391-6.
Wagner, W., Plekkenpol, B., Gray, T.E., Vlaskamp, H., Essers,
H. (1992). Review of fluvoxamine safety database. Drugs;
43(Suppl 2): 48-54.
West, R. (1993). Proposal for Newfoundland Centre for Drug
Effectiveness: A background paper for discussions between the
School of Pharmacy, Memorial University of Newfoundland and
the Newfoundland Pharmaceutical Association. Unpublished
manuscript.
Widmer, R.B., Cadoret, R.J., Troughton, E. (1983). Compliance
characteristics of 291 hypertensive patients from a rural
midwest area. The Journal of Family Practice. 17 (4); 619-25.
160
APPENDICES
[61
Appendix 1
Complete List of Antidepressants in Database
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Table A1: ComDI.... Us< of All Anti Found in database
TRADE NAME ClASS TYPE DIN DOSE
SERZONE ATYPICAL Nefrazodone 2087383 150
SERZONE ATYPICAL Nefrazodone 2087375 100
SERZONE ATYPICAL Nefrazodone 2087391 200
NQVQ-MAPROnUNE HETER Maprotiline 2158639 75
LUOIOMIL HETER Maprotiline 641855 10
NOVO-MAPROTILINE HETER Maprotiline 2158612 25
LUCIOMIL HETER Maprotillne 360481 25
LUOIQMIL HETER Maprotiline 360503 50
LUOIOMIL HETER Maproliline 360511 75
NOVO-TRAZOOONE HETER Truodone 2144298 150
SYN·TRAZOOONE HETER Trazodone 2053209 150
OESYREL HETER Trazodone 579351 50
DESYREL HETER T..zodooe 579378 100
OESYREL HETER Trazodooe 7022n 150
SYN-TRAZOOONE HETER Trazodone 2053187 50
SYN-TRAZOOQNE HCL HETER Trazooone 2053195 100
NOVO-TRAZODONE HETER Trazodone 2144271 100
APe-TRAZODONE HETER Trazodone 2147637 50
APe-TRAZODONE HETER Trazodone 2147645 100
APe.TRAZODONE HETER Trazodone 2147653 150
PM5-TRAZODONE HETER Trazodone 1937227 50
PMS·TRAZODONE HETER Trazodane 1937235 100
NOVO·TRAZOOONE HETER Trazodone 2144263 50
MANERIX MAO[ Moclobemide 899356 150
MANERIX MAO[ Moclobemide 899348 100
MANERIX MAO[ Modobemide 2166747 300
NARDIL MAO[ Phenelzine 476552 15
PARNATE MAO[ Tranylcypromine 27111 10
PARNATE MAO[ Tranylcypromine 1919598 10
EFFEXOR SNRJ Venlfaxine 2103702 75
EFFEXOR SNRI Venlfaxine 2103680 37.5
PMs.FLUOXETlNE SSR[ F1uoxetine 21n581 20
NOVQ-FLUOXE'TINE 55R[ F1uoxeline 2216582 10
PROZAC 55R[ F1uoxeline 2018985 10
APo-FLUOXETlNE SSRI Fluoxeline 2216361 20
PROZAC SSRI Fluoxetine 636622 20
PMS-FLUOXETINE SSRI Fluoxetine 21n519 10
NOVo-FLUOXETINE SSRI Fluoxetine 2216590 20
PROZAC SSRI Fluoxetine 1911021 20
NU·FlUOXETlNE SSRI fluoxetine 2192764 20
NU--FlUOXETINE SSRI Fluoxetine 2192756 10
lUVOX SSRI Fluvoxamine 1919342 50
[6)
LUVOX SSRI Auvoxamlne 1911872 '00
LUVOX SSRI Auvoxamine 1911856 SO
LUVOX SSRJ Fluvoxamine 1919369 100
PAXlL SSRI Parnxetine 1940473 30
PAXlL SSRJ Paroxeline 194001' 20
ZOLOFT SSRI 5ertraline 1962817 SO
ZOLOFT SSRI SertraJine 1962779 '00
ZOLOFT SSRI 5ertraline 2132702 25
NOVO-TRIPTYN TRICYCUC Amitriptyline 37427 SO
NOVo-TRIPTYN TRICYCLIC Amitriptyline 37400 10
APO-AMITRIPTYUNE TRICYCLIC Amitriptyline :l3S088 SO
ElAVlL TRICYCLIC Amitriptyline 16330 25
APO-AMITRIPTYUNE TRICYCLIC Amitriptyline 335061 25
APO-AMITRIPTYUNE TRICYCLIC Amitriptyline 335053 '0
PM5-AMITRIPTYUNE TRICYCLIC IAmItri"'~;oe 654515 25ELAVIL TRICYCLIC 16349 50
ELAVIL TRICYCLIC 354295 75
PMS-AMITRIPTYLINE TRICYCLIC 654523 10
NOVO-TRIPTYN TRICYCLIC Amitriptyline 37419 25
LEVATE TRICYCLIC Amitriptyline 405612 75
APO-AMITRIPTYLINE TRICYCLIC Amitriptyline 754129 75
ELAVIL TRICYCLIC Amitriptyline 16322 10
ELAVTL TRICYCLIC Amitriptyline 16306 10
ASENDIN TRICYCLIC Amox8pine 5270a. 25
ASENDIN TRICYCLIC Amoxapine 527092 SO
ASENDIN TRICYCLIC Amoxapine 527106 '00
GEN-CLOMIPRAMINE TRICYCLIC Clomipramine 2139340 '0
GEN-CLOMIPRAMINE TRICYCLIC Ciomipramine 2139359 25
APO-CLOMIPRAMINE TRICYCUC Clomipramine 2040n8 25
GEN-CLOMIPRAMINE TRICYCLIC Clomipramine 2139367 SO
ANAFRANIL TRICYCLIC Clomipramine 402591 SO
ANAFRANIL TRICYCLIC Clomipramine 324019 25
APO-CLOMIPRAMINE TRICYCLIC Clomipramine 2040751 SO
ANAFRANIL TRICYCLIC Clomipramine 330566 '0
APO-CLOMIPRAMINE TRICVCUC Clomipramine 2040786 '0
PERTOFRANE TRICYCLIC Desipramine 893765 SO
NORPRAMIN TRICYCLIC Desipramine 2024888 10
NORPRAMIN TRICYCLIC Desipramine 2024896 25
DESIPRAMINE TRICYCLIC Desipramine 1948792 SO
DESIPRAMINE TRICYCLIC Desipramine 1948784 25
DESIPRAMINE HYDROCHLORIDE TRICYCLIC Desipramine 1948776 10
NORPRAMIN TRICYCLIC Desipramine 425265 75
NQRPRAMIN TRICYCLIC Desipramine 776157 10
PMS DESIPRAMINE HYDRO TRICYCLIC Desipramine 1946277 SO
PMS DESIPRAMINE HYDRO TRICYCLIC Desipramine 1946269 25
1&1
NORPRAMIN TRICYCLIC Desipramine 2103583 '0
NORPRAMIN TRICYCUC Desipramine 353876 ,.
NORPRAMIN TRICYCLIC Desipramine 2099'''' 75NORPRAMIN TRICYCLIC Desipr.lll1ine 2099128 25
PMS DESIPRAMINE HYDRO TRJCYCLIC Desipramine 1946242 75
NORPRAMIN TRICYCLIC Desipramine 2024918 ,.
PERTOFRANE TRICYCLIC Desiprnmine ,..... 25
NORPRAMIN TRICYCLIC Desipramine 2024926 75
DESIPRAMINE TRICYCLIC Desipramine 1948806 75
NORPRAMIN TRICYCLIC Desipramine 2024934 '00
NORPRAMIN TRICYCLIC Desipramine 353868 25
PMS DESIPRAMINE HYDRO TRICYCLIC Desipramine 1946250 '0
TRlAQAPIN TRICYCLIC Doxepin 629308 100
TRIAOAPIN TRICYCLIC Doxepin 629294 75
SINEQUAN TRICYCLIC Doxepin 584274
'"SINEQUAN TRICYCLIC Doxepin «10750 75
SINEQUAN TRICYCLIC Doxepin 24325 '0
SINEQUAN TRICYCUC Doxepin 2U41 ,.
NOVO-OOXEPIN TRICYCLIC Doxepin 19130476 ,,.
SINEQUAN TRICYCUC Doxepin 326925 '00
SINEQUAN TRICYCLIC Doxepin 24333 25
NOVQ.OOXEPIN TRICYCLIC Doxepin 1913433 50
APO-OOXEPIN TRICYCLIC Doxepin 2049996 10
APQ.OOXEPIN TRICYCLIC Doxepin 2050005 25
APO-OOXEPIN TRICYCLIC Doxepin 2050013 50
APQ.OOXEPIN TRICYCLIC Doxepin 2050021 75
APO-OOXEPIN TRICYCLIC Ooxepin 2050048 '00
APO-OOXEPIN TRICYCLIC Doxepin 2050056 150
NOVO-OOXEPIN TRICYCLIC Ooxepin 1913441 75
NOvo-DOXEPIN TRICYCLIC Doxepin 1913468 '00
NOvo-DOXEPIN TRICYCLIC Doxepin 19130425 25
TRIAOAPIN TRICYCLIC Doxepin 1542753 25
RHo-DOXEPIN TRICYCUC Doxepin 2144158 50
KENRAL-DOXEPIN TRICYCLIC Doxepin 21«1071 10
KENRAL..QOXEPIN TRICYCLIC DoxelM 2140098 25
TRlAOAPIN TRICYCLIC Doxepin 842745 10
NOVO-PRAMINE TRICYCLIC Imipramine 21504 10
APO-IMIPRAMINE TRICYCLIC Imipramine 326852 50
APO-IMIPRAMINE TRICYCLIC Imipramine 360201 10
NOVO·PRAMINE TRICYCLIC Imipramine 21520 50
APO-IMIPRAMINE TRICYCLIC Imipramine 312797 25
NOVQ.PRAMINE TRICYCLIC Imipramine 21512 25
TOFRANIL TRICYCLIC Imipramine 10472 25
TOFRANIL TRICYCLIC Imipramine ,.... '0
TOFRANIL TRICYCUC Imipramine
' ....7 75
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~IMIPRAMINE TRICYCUC Imipramine ....57. 75
TOFRANIL TRICYCUC Imipramine
''''0 SO
AIIENTYL TRICYCUC Nortriptyline 15237 25
AIIENTYL TRICYCUC Nortriptyline 15229 10
TRIPTlL TRICYCUC Prntriptyline 3227..1 10
SURMONTlL TRICYCLIC Trimipramine 1926330 SO
APQ.TRIMIP TRICYCLIC Trlmipramine 7..0799 12.5
APQ.TRIMIP TRICYCLIC Trimipramine 7"0802 25
APQ.TRIMIP TRICYCLIC Trimipramine 7"0810 SO
APQ.TRIMIP TRICYCLIC Trimipramine 740829 '00
RHOTRIMINE TRICYCLIC Trimipramine 761605 12.5
RHOTRIMINE TRICYCLIC Trimipramine 761613 2S
RHOTRIMINE TRICYCUC Trimipramine 761621 SO
SURMONTIL TRICYCUC Trimipramine 442437 75
APQ.TRIMIP TRICYCLIC Trimipramine 2070987 75
RHOTRIMINE TRICYCLIC Trimipramine 761656 75
NU-TRIMIPRAMINE TRICYCLIC Trimipramine 2020602 25
SURMONTlL TRICYCLIC Trimipramlne 1926322 25
SURMONTIL TRICYCLIC Trimipramine 1926349 75
SURMONTIL TRICYCLIC Trimipramine 1926357 12.5
SURMONTIL TRICYCLIC Trimipramine 25828 17...3
SURMONTIL TRICYCLIC Trimipramine 25838 34.86
SURMQNTlL TRICYCLIC Trimipramine 2S844 69.72
NOVQ.TRIPRAMINE TRICYCUC Trimipramine 1940430 25
NOVO-TRIPRAMINE TRICYCUC Trimipramine ,....... SO
NOVO-TRIPRAMINE TRICYCLIC Trimipramine 1940..57 100
NU-TRIMIPRAMINE TRICYCLIC Trimipramine 2020610 SO
NU·TRIMIPRAMINE TRICYCLIC Trimipramine 2020599 12.5
SURMONTIL TRICYCLIC Trimipramine 1926284 100
Heter-Heterocyclic
SSRJ - Selective Serotonin Re-uptake Inh.ibitors
SNRI" Seleem.-e Norepinepl1rtne Re-uplake lnhibitOfS
MAOI" Monoamine O:cidase lnhibitors
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Appendix 2
Sample of Data Obtained From. Blue Cross
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Table A2~ Sanv e of Data Found fn Files Obtained From Blue Cross
I y
2 24572 16322 ElAVlL 24107/95 60 60 $2.40
2 62362 16322 ElAVlL 23109195 60 60 $2.40
2 95610 16322 ElAVlL 22111195 60 60 $2.40
2 128015 16322 ElAVlL 22101/96 60 60 $2.40
2 158849 16322 ElAVlL 211031'96 60 60 $2.40
3 24612 2018985 PROZAC 26107/95 60 60 $5.00
3 62384 2018985 PROZAC 22Jll9I9. 60 60 $5.00
3 95644 2018985 PROZAC 23111195 60 60 $5.00
3 128040 2018985 PROZAC 25101/96 60 60 $5.00
3 158868 2018985 PROZAC 20103196 60 60 $5.00
3 180672 2018985 PROZAC 13105196 60 60 $5.00
3 208664 2018985 PROZAC 14107196 60 60 $5.00
3 222066 2018985 PROZAC 05108196 60 60 $5.00
3 228827 2018985 PROZAC 20108196 60 60 $5.00
3 241738 2018985 PROZAC 24109196 60 60 $5.00
4 28189 306487 TOFAANIL 19107195 30 30 $7.90
4 446'2 306487 TOFRANIL 16108195 30 30 $7.90
4 44614 306487 TOFRANll 16108195 36 36 $7.90
4 646.7 306467 TOFRANll 18109195 30 30 $7.90
4 81065 306467 TOFRANll 17/10195 30 30 $7.90
4 97654- 306467 TOFRANll 16111/95 30 30 $7.90
4 113592 306467 TOFRANll 16/12195 30 30 $7.90
4 121556 306467 TOFRANll 11101/96 30 30 $7.90
4 138107 306467 TOFRANll 14102196 30 30 $7.90
4 152882 306467 TOFRANll 15103196 30 30 $7.90
4 167627 306467 TOFRANIL 13104196 30 30 $7.90
4 182172 306467 TOFRANIL 09105196 30 30 $7.90
4 196749 306487 TOFRANIL 111116196 30 30 $7.90
4 236537 1940481 PAXIL 13109/96
"
30 $7.90
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Appendix 3
Letter of Approval From Blue Cross
..9
07 October 1996
Ms. lynette Powell
RaardI A.Wstant
Gndowe Student
Memorial UDivonrty ofNewfoundlaod
Division ofCommunity Medicine
FK:U!ty ofMedicine
The Health Sciences Centre
SL John's. NewfOUDdland
AlB1V6
Dear lynette:
This letter is to confirm that: Blue Cross is wiI1ing to provide dau in suppon oCme study to
determine whether rdiU complWx;e to antidepressant medication varies in relation to different
1Klo".
To ensure con6dentia1ity of the data, we will require an agreernem: to be signed by Memorial
UnMrsity. A copy of the agreement will be sent to you as soon as POSSIble.
I apologize foc the delays experienced ttw far in obtaining the requested cW:a.. We will mdeavour
to provide you with the data as quicldy &5 posable. Ifyou have any questions. pJeue do DDt
besit:ate to contact me..
Yountrulv.
°Ahe:sfe Madnnis
Health Care Professional" Provider hlarions .~~.E...ROSS
~ IolAaNNJS •
tIQlhCueProl'essionalIlldProorillerItdaliofts("'>"''''''._(!IIt).,~
_'-iJ<PO_DIl auo
-IIaIlCIU"_IIaIICIU
Appendix 4
Human Investigations Corrmittee Approval
110
ottice of Raean:h Uld C~dUolteScudies IMedic:mel
FKu1tyo! Medicirlc
1'he He&lth SdcrKes Ca:u:n:
21 October 1996
TO: Ms. Lynene Powell
nOM: Dr. Verua M. SIwIes, Assiswl. Deal1
Resun:b &: G_ Studies (MediciDe)
SUBJECI': AppljqrioQ to tbe Human [JMjSliptioP Cgmgriu«. #961+4
The Human Investigatioo Comminee of the Faculty of MediciDe bas tmewed your proposal
for the study entitled -Faeton AJI'ectiq ReftlI Adbereac:e After tJae SCart of New Coana
ot Sele<1he _1l1a ....pUke Illh1bl..... ucI 'I'riq<11c: ADddep..........".
Full approval bas been granted for ODe year, from point of view of ethics as defined in the
terms of reference of this Family Committee.
For a bospital-based study, it is mgr mmns1bJllty to _k Decay" .ppmn.I trow tM
fkalt' em CorponCkm pC St. Job•• s.
Notwithstanding the approYal of the me. the primary respoosibility for the ethical conduct
of the iavestigation remains with you..
Verna M. sane( Ph.D.
Assistant Dean
oc Dr. K.M.W. JCeou&.h, Vice·Presidcnt (Research)
Dr. E. Parsons. Vice-Presideot, Medical Services., HCC
Dr. R. West, Supervisor
$I:. John".. NF. Cmad& AIBJV6· Tel: r7'09' 737~62. Faa: I709l 737-Xl.lJ. eaWl: 'P.lDI:XpZLlICI..............
~ _. ------ -----
... U~tyof NewfoundWld
HUlIWI lnvaciptior1 Comminer
RcscatchmdGndl,LlIe~
FKUity ot. Medicine
The HeUth .5<:ierla:5 C=tte
21 October 1996
Ms.4n<~P"""U
Division of ColDll1UDity Medidne
Dear Ms. Powell;
AI: a meetin&: of me Human Investigation Committee held on Odober l~ tfH. your
applic:atiOQ entitled "FadOn AtrectIq IWIIl AdIIeteKt After Ih Start 01 New Coanes of
SeIed.tft SerotoD.ia Rnptake IalLibiaon ud TricJdic AalidepftSSallls" was coosidcred and
appTOYal recommended.
We take this opportuDicy to wish you every suc:c:ess with your research study.
K!r.YOUll8busbaJld(Ph.D.
Cbairman
Human lDv~tioQCommittee
HBY\jg1o
<X Dr. K.M.W. Keough. Vice-President, Research
Dr. Erie Parsoos. Vice-President, Medical Services. HCC
Dr. Roy West, Supervisor
Sf. John"s. N'F.~ AlI3V6. Tel, OOP'I n7~4. Fu::: l7'09I737-30033
Appendix 5
Normal and Logarithmic Transformation of
Percentage of Non-compliant Days
'71
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Appendix 6
Raqression Model for Percentage of
Non-compliant Days Analysis
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Table A); RegnssiOD Model ror Tricyclic and SSRI men with percentage or non-
compliant d.ays >0
Model
1
2 0.017
Model I; Predictors; Number ofdoses per day
Model 2; Predictors; Number ofdoses per day and number ofconcurrent medications
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Appendi.x 7
Survival Curves for 30 Day Assumption
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Appendix 8
Survival Curves for Non-significant Variables
for 15 Day Assumption
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Table A-4 Pairwise aDd OytraU C_parilotu: alii_ 10 DO~pliaDce rOf" the Varioas Lcvds of tbe
P • VuiablcsrortheT' die
C_'PUi- Type WiIcoJ:u; for IS cb:y
--....WI .003....95'
Ovcr.tD (10 pain) W(-4)-15.n. p-.OOJ
<20 and 21·35 Pairwise W(I)-1.I6.p-.2SI W(I)-US. p-.002-
<20 and 36-55 ~ W(I)-5.68.p-.017 W(I)-S.18.p-JJO.l.*
21·)5 and 36-55 ~ W(I)-1.95.p=.163 W(I)-I.22. p-.270
<20 and 51-65 Pairwise W(I)-5.J.J.p-.021 W{I)-8.22.p-.0Q0I.*
21-)5 and 51-65 Painvisc W(I)-1.54.p-.2lS W(I)"'l.OO.p"'.317
36·SSandSL-65 Pairwise: W(I)-O.2J.p-.6JJ W(()'=O.04. p=.847
<20 and >65 Pairwise W(I)-IJ.96. p=.OOO* W(l)-I0.8S. p-.ool*
21-)5 and >65 Pairwise W(I)-9.IS. p=.OO2* W{I)-O.IS.p-.676
J6.5S and >65 ~ W(I)a5.82. pz.016 W(l)=290. p=.089
51-65 and >65 Pairwise W(I)-7.ll. p=.OO7 W(I)-2.52.p-.113
ColICDrrtIllDrup Ch"IC:rall (10 pairs} W(4)-2'-OJ. p=.OOO" W(4)-15.U. p-.004·
ComparUoas;
.... , PaiI'l'Uc W(I}-0.J4.p-.559 W(I}-(l.U.p-.S27
.,",,2 ~ W(I)-6.40. p=.011 W(1pI.J6. p=.H3
''''''2 Pairwise W(I~.60. p"".032 W(I)-2.15.!p. I·U
OandJ.... ~ W(I)-8.S7.p-.OOJ* W(I~.J9.p-.036
I and J .... W(I)-6.S5. p-.OO9 W(I}-6.54. p-.01O
2 and J-4 Pairwise W(I)o<O.I3.p-.72J W(I)-L26. p-.26J
o and >-5 Pairwise W(I)-17.32. p=.OOO· W(I)-'7.72. p=.OO5
I and >-5 Pairwise W(I)-I5.73.p=o.OOO* W(I)-W.27. p=.OOI*
2 and >-5 Pairwise W(I)"'-'.J8. pz.036 W(I)-4.J7. p=.OJ7
J-4and >-5 Pairwise Wm-3.S0. p=.061 W(1}'='1.34. p=.2~7
NlilDberlD.av Qve.......1(2 painj W 1)-JO.21. D-J}OO· W:n-17.79. p -.000·
Avgcost orOlhcr Overall(J pairs) W(2}-&.OO.p-.1J5 W(2)-2.6J.p-.268
D~..
<$.J.oo and $4.01- Painvise W(l)-4.08. pz.043 W(1)e2.67.p-.102
8.00 Pairwise W(I)-O.64.p-A2J W(I)-O.5J. p-.468
<$1.00 and >$8.00 ~ W(I)-OA3.p=.-l89 W(I)-O.lS. p-.616
$4.01-3.00 and
>$8.00
AvgCOflor Oytrall(J Pain) W(l)-1.i'.p-.li W(2)-l.IlJ. p-.401
aatidcprcssanu
<$UO and $4.01-8.00 Pairwise W(I)-2.56.p-=O.t09 W(I)-o.88. p-.J~7
<$1.00 and >$S.OO Pairwise W(I)-O.62.p-(I.4J2 W(I)"'UJ.p=.233
$4.01.-8.00 and ~ W(lpO.O~. JPO.839 W(I>-O.J~.p-.556
>$8.00
~for15da1
1-
WI .OS• .B1
Table AS: Pairwise:IQd Ovenall CompuUocu of riJDe (0 IMll1-C01DpliaPSe (or tAte Varioes Le>'ds of
~ • rV~~fur m ~
Variable C..,.....Type
<20md 21-35
<20 and 36-55
21·J5md36·55
<20 and 51-65
21-35and5t-65
36-55 and 51-65
<20 and >65
21·35 and >65
36-55 and >65
51-65 and >65
COOCUrftDl Dnlp
Coc.puUolaJ;
.'"'" I
.'""',
''"''''o and 34
I and 34
2 and 34
oand =-5
I and >-5
2 and >-5
34 and >-5
NumberlDav
Al'gcostoiOthcr
ON"
<$.1.00 and 5-1.01-
8.00
<$.1.00 and >$8.00
$oUI-8.00 and
>$8.00
A~l;costof
aatideprltlSaoU
<$.1.00 and SoI.OI-8.00
<$.1.00 and >$8.00
5-1-.01-8.00 and
>$8.00
~n1I(IOpairs)
Pairwise
Pairwise
"""""
"""""Pairwise
Pairwise
Pairwise
"""""
"""""Pairwise
(h"f:n1I (10 p:lin)
"""""Pairwise
Pairwise:
Pairwise
Pairwise:
Pairwise:
PairnUe
Painvise
Pamvise
Pairwise
(h"f:nJl 2 airs
Onrall (J pain)
(h'enJl (3 Pairs)
"""""Pairwise
Painvise
W(I)-OJ).I.p-.85
W(1)-0.5j. p-..n
W(I)-1.l4.p=.29
W(I)-IAO. p=.24
W(I)-J.S4. p-.06
W(I)-L23.p=".27
W(I)-t.oJ.p<>.31
W(t)="1.24.p-.26
W(l)aO.27. p-.61
W(l)aO.OO. p=.99
W(")-IS.IS. p=.OOI*
W(I)-6.I5.p-.OIJ
W(IFIO.ILp-.OO2*
W(1)-o.91. p-.342
W(I)-12.1S. p=.OOO·
W(I)-I.86. p-.I12
W(1)-o.ll. p-.6U
W(1)-S.S7. p=.OIS
W(I)=O.62.p-A33
W(t}-O.OI, p=.9SI
W(I)-O.08. p=.172
WI .10, .00*
W(I)-O.OLP"".94
W(I)-O.30. p-.60
W(I)-o.JJ.p-.57
W(2)-6.IO, p-.033
W(I)-O.OI. p-O.941
W(I)-J.SS. p=O.OS9
W(I)-6.OO. p=O.OI4"'
W(I}-O.29.p-.S9
W(I ... I...... p-.23
W(I)-1.S9.p=.21
W(I>-O·~.IFA3
W(I)-O.24.P"".63
W(I)-O.S7. p-AS
W(t)-OA9.p-AS
W(I)aO.lS.p-.67
W(I)-o.07. p-.79
W(l)-O.OO. p-.96
W(")-6.JO. pz.l71
W(I)-O.38.p=.539
W(I .... I.8-I.p-.175
W(I)cO.66. pz-II8
W(I)-4...... p-.OJ5
W(I)-Hl. p-.116
W(t)'"OA5.p<"'.SO)
W(I)o=2A9.pa.llS
W(1l"'1.51.p=.220
W(I)-O.2S.p-.617
W(IP'O.OI.p=.9.f2
W(l ..." -.0.*
W(2)-J.47.,...IS
W(i}-'O.90. p-.34
W(I)-U8. p-.06
W(I)-I.41.p-.2J
W(2)-6.36, p-.O·U
W(l)aO.OI. p=.926
W(I)-J.23.p-.072
W(1)=S.S4.p-.OI9
"'Signi.ficant althe modified. alpha level (see Table 4.12)
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